CUMULATIVE SUPPLEMENT 03
March 2007



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

27th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2007

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

27th EDITION

Cumulative Supplement 03

March 2007

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

27th EDITION

CUMULATIVE SUPPLEMENT 03
March 2007

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 27th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 26th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 27th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@cder.fda.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BIONICHE PHARMA (BIONICHE PHARMA)	BIONICHE PHARMA USA LLC (BIONICHE PHARMA)
BIONICHE PHARMA (CANADA) LTD (BIONICHE (CANADA))	BIONICHE PHARMA USA LLC (BIONICHE PHARMA)
BIONICHE PHARMA USA INC (BIONICHE PHARMA USA)	BIONICHE PHARMA USA LLC (BIONICHE PHARMA)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.fda.gov/cder/ob/default.htm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Annual Edition. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://www.bookstore.gpo.gov/; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/cder/orange/obreadme.htm . The drug product text files are provided in eobzip.exe and eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt,

ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2006	MAR 2007	JUN 2007	SEPT 2007
DRUG PRODUCTS LISTED	11896	12063		
SINGLE SOURCE	2471 (20.8%)	2471 (20.5%)		
MULTISOURCE	9336 (78.5%)	9503 (78.8%)		
THERAPEUTICALLY EQUIVALENT	9139 (76.8%)	9320 (77.3%)		
NOT THERAPEUTICALLY EQUIVALENT	197 (1.7%)	183 (1.5%)		
EXCEPTIONS[1]	89 (0.7%)	89 (0.7%)		
NEW MOLECULAR ENTITIES APPROVED	10	4		
NUMBER OF APPLICANTS	666	675		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.

CTNA Change. Trade Name.
DISC Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABARELIX

INJECTABLE; INTRAMUSCULAR
PLENAXIS
@ SPECIALITY EUROPEAN 100MG/VIAL N21320 001 Nov 25, 2003 Feb CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

>A>	AA		BOCA PHARMA	356.4MG;30MG;16MG	N40688	001	Apr 03, 2007	Mar	NEWA
>D>		+	MIKART	356.4MG;30MG;16MG	N40109	001	Aug 26, 1997	Mar	CTEC
>A>	AA	+		356.4MG;30MG;16MG	N40109	001	Aug 26, 1997	Mar	CTEC

TABLET; ORAL
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

>A>	AA		BOCA PHARMA	712.8MG;60MG;32MG	N40701	001	Apr 03, 2007	Mar	NEWA
	AA	+	MIKART	712.8MG;60MG;32MG	N40316	001	Apr 28, 1999	Feb	CTEC
	AA		WEST WARD	712.8MG;60MG;32MG	N40637	001	Sep 22, 2006	Feb	CTEC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA		INTERPHARM	500MG;10MG	N40813	001	Feb 23, 2007	Feb	NEWA

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>A>	AB		WOCKHARDT	325MG;50MG	N77677	001	Mar 16, 2007	Mar	NEWA
>A>	AB			650MG;100MG	N77677	002	Mar 16, 2007	Mar	NEWA

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL

>D>	AB		ARMSTRONG PHARMS	0.09MG/INH	N72273	001	Aug 14, 1996	Mar	CRLD
>A>		+		0.09MG/INH	N72273	001	Aug 14, 1996	Mar	CRLD
>D>	AB		IVAX PHARMS	0.09MG/INH	N73272	001	Dec 28, 1995	Mar	DISC
>A>			@	0.09MG/INH	N73272	001	Dec 28, 1995	Mar	DISC
>D>			VENTOLIN						
>D>	AB	+	GLAXOSMITHKLINE	0.09MG/INH	N18473	001		Mar	DISC
>A>			@	0.09MG/INH	N18473	001		Mar	DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

	AN		APOTEX INC	EQ 0.083% BASE	N75717	001	Feb 02, 2007	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
ALBUTEROL SULFATE

	AB		MYLAN	EQ 4MG BASE	N78092	002	Jan 29, 2007	Jan	NEWA
	AB			EQ 8MG BASE	N78092	001	Jan 29, 2007	Jan	NEWA
			VOSPIRE ER						
	AB		DAVA PHARMS INC	EQ 4MG BASE	N76130	002	Sep 26, 2002	Jan	CTEC
	AB	+		EQ 8MG BASE	N76130	003	Sep 26, 2002	Jan	CTEC

>A>		ALISKIREN HEMIFUMARATE							
>A>		TABLET; ORAL							
>A>		TEKTURNA							
>A>		NOVARTIS	EQ 150MG BASE	N21985	001	Mar 05, 2007	Mar	NEWA	
>A>		+	EQ 300MG BASE	N21985	002	Mar 05, 2007	Mar	NEWA	
		ALPRAZOLAM							
		TABLET; ORAL							
		ALPRAZOLAM							
	AB	APOTEX INC	0.25MG	N77741	001	Jan 19, 2007	Jan	NEWA	
	AB		0.5MG	N77741	002	Jan 19, 2007	Jan	NEWA	
	AB		1MG	N77741	003	Jan 19, 2007	Jan	NEWA	
	AB		2MG	N77741	004	Jan 19, 2007	Jan	NEWA	
>D>		@ DAVA INTL INC	0.25MG	N74174	001	Oct 19, 1993	Mar	CMFD	
>A>	AB		0.25MG	N74174	001	Oct 19, 1993	Mar	CMFD	
		@	0.25MG	N74174	001	Oct 19, 1993	Feb	CAHN	
>D>		@	0.5MG	N74174	002	Oct 19, 1993	Mar	CMFD	
>A>	AB		0.5MG	N74174	002	Oct 19, 1993	Mar	CMFD	
		@	0.5MG	N74174	002	Oct 19, 1993	Feb	CAHN	
>D>		@	1MG	N74174	003	Oct 19, 1993	Mar	CMFD	
>A>	AB		1MG	N74174	003	Oct 19, 1993	Mar	CMFD	
		@	1MG	N74174	003	Oct 19, 1993	Feb	CAHN	
>D>		@	2MG	N74174	004	Oct 19, 1993	Mar	CMFD	
>A>	AB		2MG	N74174	004	Oct 19, 1993	Mar	CMFD	
		@	2MG	N74174	004	Oct 19, 1993	Feb	CAHN	
		TABLET, EXTENDED RELEASE; ORAL							
		ALPRAZOLAM							
	AB	ACTAVIS ELIZABETH	0.5MG	N78056	001	Feb 13, 2007	Jan	NEWA	
	AB		1MG	N78056	002	Feb 13, 2007	Jan	NEWA	
	AB		2MG	N78056	003	Feb 13, 2007	Jan	NEWA	
	AB		3MG	N78056	004	Feb 13, 2007	Jan	NEWA	
	AB	COREPHARMA	0.5MG	N77996	001	Jan 31, 2007	Jan	NEWA	
	AB		1MG	N77996	002	Jan 31, 2007	Jan	NEWA	
	AB		2MG	N77996	003	Jan 31, 2007	Jan	NEWA	
	AB		3MG	N77996	004	Jan 31, 2007	Jan	NEWA	
	AB	TEVA PHARMS	0.5MG	N77979	001	Feb 28, 2007	Feb	NEWA	
	AB		1MG	N77979	002	Feb 28, 2007	Feb	NEWA	
	AB		2MG	N77979	003	Feb 28, 2007	Feb	NEWA	
	AB		3MG	N77979	004	Feb 28, 2007	Feb	NEWA	
		TABLET, ORALLY DISINTEGRATING; ORAL							
		NIRAVAM							
		+ SCHWARZ PHARMA	1MG	N21726	003	Jan 19, 2005	Jan	CRLD	
			2MG	N21726	004	Jan 19, 2005	Jan	CRLD	
		AMINO ACIDS							
		INJECTABLE; INJECTION							
		NOVAMINE 11.4%							
		+ HOSPIRA	11.4% (11.4GM/100ML)	N17957	003	Aug 09, 1982	Jan	CRLD	
		NOVAMINE 15%							
		+ HOSPIRA	15% (15GM/100ML)	N17957	004	Nov 28, 1986	Jan	CRLD	
		AMOXICILLIN							
		CAPSULE; ORAL							
		AMOXICILLIN							
	AB	HIKMA PHARMS	250MG	N65291	001	Feb 05, 2007	Jan	NEWA	

CAPSULE; ORAL
AMOXICILLIN

AB		HIKMA PHARMS	500MG	N65291	002	Feb 05, 2007	Jan	NEWA

FOR SUSPENSION; ORAL
AMOXICILLIN

>A>	AB	SANDOZ	125MG/5ML	N65387	001	Mar 26, 2007	Mar	NEWA
>A>	AB		200MG/5ML	N65378	001	Mar 26, 2007	Mar	NEWA
>A>	AB		250MG/5ML	N65387	002	Mar 26, 2007	Mar	NEWA
>A>	AB		400MG/5ML	N65378	002	Mar 26, 2007	Mar	NEWA

TABLET, FOR SUSPENSION; ORAL
AMOXICILLIN

AB		AUROBINDO PHARMA	200MG	N65324	001	Jan 17, 2007	Jan	NEWA
AB			400MG	N65324	002	Jan 17, 2007	Jan	NEWA

DISPERMOX

AB		RANBAXY	200MG	N65080	002	Aug 11, 2003	Jan	CTEC
AB	+		400MG	N65080	001	Aug 11, 2003	Jan	CTEC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		RANBAXY	600MG/5ML;EQ 42.9MG BASE/5ML	N65207	002	Jan 30, 2007	Jan	NEWA

AUGMENTIN ES-600

>D>	AB	+ GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755	001	Jun 22, 2001	Mar	CAHN
>A>	AB	+ SMITHKLINE BEECHAM	600MG/5ML;EQ 42.9MG BASE/5ML	N50755	001	Jun 22, 2001	Mar	CAHN

ARIPIPRAZOLE

TABLET; ORAL
ABILIFY

		OTSUKA	15MG	N21436	002	Nov 15, 2002	Feb	CRLD
			30MG	N21436	004	Nov 15, 2002	Feb	CRLD

TABLET, ORALLY DISINTEGRATING; ORAL
ABILIFY

	+	OTSUKA	10MG	N21729	002	Jun 07, 2006	Feb	CRLD
			30MG	N21729	005	Jun 07, 2006	Feb	CRLD

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
NORGESIC

AB		GRACEWAY	385MG;30MG;25MG	N13416	003	Oct 27, 1982	Jan	CAHN

NORGESIC FORTE

AB	+	GRACEWAY	770MG;60MG;50MG	N13416	004	Oct 27, 1982	Jan	CAHN

AZATHIOPRINE

TABLET; ORAL
AZATHIOPRINE

>A>	AB	ZYDUS PHARMS USA	50MG	N77621	001	Mar 15, 2007	Mar	NEWA

AZITHROMYCIN

INJECTABLE; INJECTION
AZITHROMYCIN

AP		PLIVA HRVATSKA DOO	EQ 500MG BASE/VIAL	N65265	001	Jan 18, 2007	Jan	NEWA

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

@	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50416	002		Feb	DISC	

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

+	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N64068	001	Oct 30, 1995	Feb	CTEC	

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOSPORIN

@	MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50417	001		Feb	DISC	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

POLYSPORIN

@	MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM	N61229	001		Feb	DISC	

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

>D>	+	3M	0.04MG/INH	N20911	002	Sep 15, 2000	Mar	CAHN	
>A>	+	IVAX RES	0.04MG/INH	N20911	002	Sep 15, 2000	Mar	CAHN	

QVAR 80

>D>	+	3M	0.08MG/INH	N20911	001	Sep 15, 2000	Mar	CAHN	
>A>	+	IVAX RES	0.08MG/INH	N20911	001	Sep 15, 2000	Mar	CAHN	

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

>D>		KING PHARMS	5MG;40MG	N18647	001	May 25, 1983	Mar	CFTG	
>A>	AB		5MG;40MG	N18647	001	May 25, 1983	Mar	CFTG	
>D>	+		5MG;80MG	N18647	002	May 25, 1983	Mar	CFTG	
>A>	AB +		5MG;80MG	N18647	002	May 25, 1983	Mar	CFTG	

NADOLOL AND BENDROFLUMETHIAZIDE

>A>	AB	IMPAX LABS	5MG;40MG	N77833	001	Mar 30, 2007	Mar	NEWA	
>A>	AB		5MG;80MG	N77833	002	Mar 30, 2007	Mar	NEWA	

BENZONATATE

CAPSULE; ORAL

BENZONATATE

>A>	AA	THE PHARMA NETWORK	100MG	N40627	001	Mar 30, 2007	Mar	NEWA	

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

>A>	AA	TEDOR PHARM	50MG	N40747	001	Mar 30, 2007	Mar	NEWA	

BUDESONIDE

POWDER, METERED; INHALATION

PULMICORT FLEXHALER

	ASTRAZENECA	0.08MG/INH	N21949	001	Jul 12, 2006	Feb	CTNA	
+		0.16MG/INH	N21949	002	Jul 12, 2006	Feb	CTNA	

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

SPRAY, METERED; INHALATION
SYMBICORT

+		ASTRAZENECA	0.08MG/INH;0.045MG/INH	N21929	001	Jul 21, 2006	Jan	CAIN
+			0.16MG/INH;0.045MG/INH	N21929	002	Jul 21, 2006	Jan	CAIN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPRENORPHINE HYDROCHLORIDE

>A>	AP	PHARMAFORCE	EQ 0.3MG BASE/ML	N78331	001	Mar 27, 2007	Mar	NEWA

CABERGOLINE

TABLET; ORAL
CABERGOLINE

	AB	IVAX PHARMS INC	0.5MG	N77750	001	Mar 07, 2007	Feb	NEWA

CARBOPLATIN

INJECTABLE; IV (INFUSION)
CARBOPLATIN

>A>	AP	SICOR PHARMS	EQ 50MG/5ML (10MG/ML)	N77389	001	Mar 30, 2007	Mar	NEWA
>A>	AP		EQ 150MG/15ML (10MG/ML)	N77389	002	Mar 30, 2007	Mar	NEWA
>A>	AP		EQ 450MG/45ML (10MG/ML)	N77389	003	Mar 30, 2007	Mar	NEWA
	AP	WATSON LABS	EQ 50MG/5ML (10MG/ML)	N77861	001	Jan 18, 2007	Jan	NEWA
	AP		EQ 150MG/15ML (10MG/ML)	N77861	002	Jan 18, 2007	Jan	NEWA
	AP		EQ 450MG/45ML (10MG/ML)	N77861	003	Jan 18, 2007	Jan	NEWA
	AP		EQ 600MG/60ML (10MG/ML)	N77861	004	Jan 18, 2007	Jan	NEWA

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

	AA	SUN PHARM INDS LTD	350MG	N40755	001	Feb 27, 2007	Feb	NEWA

CEFACLOR

CAPSULE; ORAL
CEFACLOR

>A>	AB	HIKMA	EQ 250MG BASE	N65350	001	Apr 03, 2007	Mar	NEWA
>A>	AB		EQ 500MG BASE	N65350	002	Apr 03, 2007	Mar	NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL

	AB	AUROBINDO PHARMA	500MG	N65352	001	Jan 25, 2007	Jan	NEWA

CEFDINIR

CAPSULE; ORAL
CEFDINIR

>A>	AB	SANDOZ	300MG	N65330	001	Apr 06, 2007	Mar	NEWA

FOR SUSPENSION; ORAL
CEFDINIR

>A>	AB	SANDOZ	125MG/5ML	N65337	001	Apr 06, 2007	Mar	NEWA
>A>	AB		250MG/5ML	N65337	002	Apr 06, 2007	Mar	NEWA

OMNICEF

>D>		+ ABBOTT	250MG/5ML	N50749	002	Jul 29, 2004	Mar	CFTG
>A>	AB	+	250MG/5ML	N50749	002	Jul 29, 2004	Mar	CFTG

CEFIXIME

SUSPENSION; ORAL

>A>		CEFIXIME						
>A>		LUPIN PHARMS	200MG/5ML	N65355	001	Apr 10, 2007	Mar	NEWA

CEFPROZIL

FOR SUSPENSION; ORAL

		CEFPROZIL						
	AB	AUROBINDO PHARMA	125MG/5ML	N65381	001	Jan 30, 2007	Jan	NEWA
	AB		250MG/5ML	N65381	002	Jan 30, 2007	Jan	NEWA

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

		CEFIZOX						
		@ ASTELLAS	EQ 1GM BASE/VIAL	N50560	002	Sep 15, 1983	Feb	DISC
		+	EQ 1GM BASE/VIAL	N63294	002	Mar 31, 1994	Feb	CRLD

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

		CEFTRIAXONE						
>A>	AP	CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	N65294	001	Mar 26, 2007	Mar	NEWA
>A>	AP		EQ 500MG BASE/VIAL	N65294	002	Mar 26, 2007	Mar	NEWA
>A>	AP		EQ 1GM BASE/VIAL	N65294	003	Mar 26, 2007	Mar	NEWA
>A>	AP		EQ 2GM BASE/VIAL	N65294	004	Mar 26, 2007	Mar	NEWA
	AP	HANFORD GC	EQ 1GM BASE/VIAL	N65268	001	Feb 28, 2007	Feb	NEWA
	AP		EQ 2GM BASE/VIAL	N65268	002	Feb 28, 2007	Feb	NEWA
>A>	AP	SICOR PHARMS	EQ 250MG BASE/VIAL	N65227	001	Mar 15, 2007	Mar	NEWA
>A>	AP		EQ 500MG BASE/VIAL	N65227	002	Mar 15, 2007	Mar	NEWA
>A>	AP		EQ 1GM BASE/VIAL	N65227	003	Mar 15, 2007	Mar	NEWA
>A>	AP		EQ 2GM BASE/VIAL	N65227	004	Mar 15, 2007	Mar	NEWA

INJECTABLE; INJECTION

		CEFTRIAXONE						
	AP	HANFORD GC	EQ 10GM BASE/VIAL	N65269	001	Feb 28, 2007	Feb	NEWA

CELECOXIB

CAPSULE; ORAL

		CELEBREX						
		GD SEARLE	50MG	N20998	004	Dec 15, 2006	Jan	NEWA

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

		CHLORAMPHENICOL SODIUM SUCCINATE						
	+	ABRAXIS PHARM	EQ 1GM BASE/VIAL	N62365	001	Aug 25, 1982	Feb	CRLD
		CHLOROMYCETIN						
		@ PARKEDALE	EQ 1GM BASE/VIAL	N50155	001		Feb	DISC

CHLOROTHIAZIDE

SUSPENSION; ORAL

		DIURIL						
	+	SALIX PHARMS	250MG/5ML	N11870	001		Feb	CAHN

>D>			CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX							
>D>			SUSPENSION, EXTENDED RELEASE; ORAL							
>D>			CODEPREX							
>D>		+	UCB INC	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N21369	001	Jun 21, 2004	Mar	DISC	
>A>		@		EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N21369	001	Jun 21, 2004	Mar	DISC	
			CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE							
			TABLET, EXTENDED RELEASE; ORAL							
			CIPRO XR							
>D>		+	BAYER PHARMS	212.6MG;EQ 287.5MG BASE	N21473	001	Dec 13, 2002	Mar	CFTG	
>A>	AB	+		212.6MG;EQ 287.5MG BASE	N21473	001	Dec 13, 2002	Mar	CFTG	
>D>		+		425.2MG;EQ 574.9MG BASE	N21473	002	Aug 28, 2003	Mar	CFTG	
>A>	AB	+		425.2MG;EQ 574.9MG BASE	N21473	002	Aug 28, 2003	Mar	CFTG	
			CIPROFLOXACIN EXTENDED RELEASE							
>A>	AB		DR REDDYS LABS LTD	425.2MG;EQ 574.9MG BASE	N77701	001	Mar 26, 2007	Mar	NEWA	
>A>	AB		MYLAN	212.6MG;EQ 287.5MG BASE	N78183	001	Mar 22, 2007	Mar	NEWA	
>A>	AB			425.2MG;EQ 574.9MG BASE	N78183	002	Mar 22, 2007	Mar	NEWA	
			CISPLATIN							
			INJECTABLE; INJECTION							
			CISPLATIN							
>D>	AP		BEDFORD	10MG/VIAL	N74713	001	Nov 14, 2000	Mar	DISC	
>A>		@		10MG/VIAL	N74713	001	Nov 14, 2000	Mar	DISC	
>D>	AP			50MG/VIAL	N74713	002	Nov 14, 2000	Mar	DISC	
>A>		@		50MG/VIAL	N74713	002	Nov 14, 2000	Mar	DISC	
			PLATINOL							
>D>	AP	+	BRISTOL MYERS	10MG/VIAL	N18057	001		Mar	CTEC	
>A>		+		10MG/VIAL	N18057	001		Mar	CTEC	
>D>	AP	+		50MG/VIAL	N18057	002		Mar	CTEC	
>A>		+		50MG/VIAL	N18057	002		Mar	CTEC	
			CITALOPRAM HYDROBROMIDE							
			CAPSULE; ORAL							
			CITALOPRAM HYDROBROMIDE							
			ALPHAPHARM	EQ 10MG BASE	N77668	001	Feb 28, 2007	Feb	NEWA	
				EQ 20MG BASE	N77668	002	Feb 28, 2007	Feb	NEWA	
		+		EQ 40MG BASE	N77668	003	Feb 28, 2007	Feb	NEWA	
			TABLET; ORAL							
			CITALOPRAM HYDROBROMIDE							
>A>	AB		TORRENT PHARMS	EQ 10MG BASE	N78216	001	Mar 27, 2007	Mar	NEWA	
>A>	AB			EQ 20MG BASE	N78216	002	Mar 27, 2007	Mar	NEWA	
>A>	AB			EQ 40MG BASE	N78216	003	Mar 27, 2007	Mar	NEWA	
			CLINDAMYCIN PHOSPHATE							
			INJECTABLE; INJECTION							
			CLINDAMYCIN PHOSPHATE							
>A>	AP		ABRAXIS PHARM	EQ 150MG BASE/ML	N65346	001	Mar 29, 2007	Mar	NEWA	
			CLOBETASOL PROPIONATE							
			AEROSOL, FOAM; TOPICAL							
			OLUX E							
		+	CONNETICS	0.05%	N22013	001	Jan 12, 2007	Jan	NEWA	

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE

AT	ALTANA	0.05%	N75391	001	Feb 08, 1999	Feb	CMFD	

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HYDROCHLORIDE

AB	VINTAGE	0.1MG	N77901	001	Mar 09, 2007	Feb	NEWA	
AB		0.2MG	N77901	002	Mar 09, 2007	Feb	NEWA	
AB		0.3MG	N77901	003	Mar 09, 2007	Feb	NEWA	

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
AMRIX

	ECR	15MG	N21777	001	Feb 01, 2007	Feb	NEWA	
+		30MG	N21777	002	Feb 01, 2007	Feb	NEWA	

TABLET; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB	VINTAGE PHARMS	5MG	N77797	001	Feb 28, 2007	Feb	NEWA	
AB		10MG	N77797	002	Feb 28, 2007	Feb	NEWA	

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL
DECLOMYCIN

>D>	@ GLADES PHARMS LLC	75MG	N50261	001		Mar	CAHN	
>D> AB		150MG	N50261	002		Mar	CAHN	
>D> AB +		300MG	N50261	003		Mar	CAHN	
>A>	@ STIEFEL	75MG	N50261	001		Mar	CAHN	
>A> AB		150MG	N50261	002		Mar	CAHN	
>A> AB +		300MG	N50261	003		Mar	CAHN	

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

>A> AB	ACTAVIS TOTOWA	10MG	N74430	001	Feb 09, 1996	Mar	CAHN	
>A> AB		25MG	N71601	001	Jun 05, 1987	Mar	CAHN	
>A> AB		75MG	N71602	001	Oct 05, 1987	Mar	CAHN	
>A> AB		100MG	N71766	001	Oct 05, 1987	Mar	CAHN	
>A> AB		150MG	N74430	002	Feb 09, 1996	Mar	CAHN	
>A> AB	AMIDE PHARM	50MG	N71588	001	Jun 05, 1987	Mar	CAHN	
>D> AB	SANDOZ	10MG	N74430	001	Feb 09, 1996	Mar	CAHN	
>D> AB		25MG	N71601	001	Jun 05, 1987	Mar	CAHN	
>D> AB		50MG	N71588	001	Jun 05, 1987	Mar	CAHN	
>D> AB		75MG	N71602	001	Oct 05, 1987	Mar	CAHN	
>D> AB		100MG	N71766	001	Oct 05, 1987	Mar	CAHN	
>D> AB		150MG	N74430	002	Feb 09, 1996	Mar	CAHN	

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	TEVA PHARMS	2.5MG	N77107	003	Jan 29, 2007	Jan	NEWA	
AB		5MG	N77107	001	Jan 29, 2007	Jan	NEWA	
AB		10MG	N77107	002	Jan 29, 2007	Jan	NEWA	
	FOCALIN							
AB	NOVARTIS	2.5MG	N21278	001	Nov 13, 2001	Jan	CFTG	

TABLET; ORAL
FOCALIN
AB NOVARTIS 5MG N21278 002 Nov 13, 2001 Jan CFTG
AB + 10MG N21278 003 Nov 13, 2001 Jan CFTG

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXEDRINE
@ GLAXOSMITHKLINE 5MG N84935 001 Feb DISC
DEXTROSTAT
>A> AA + SHIRE 5MG N84051 001 Mar CAHN
>A> AA + 10MG N84051 002 Mar CAHN
>D> AA + SHIRE RICHWOOD 5MG N84051 001 Mar CAHN
>D> AA + 10MG N84051 002 Mar CAHN

DICLOFENAC EPOLAMINE

PATCH; TOPICAL
FLECTOR
+ INST BIOCHEM 1.3% N21234 001 Jan 31, 2007 Jan NEWA

DIDANOSINE

FOR SOLUTION; ORAL
DIDANOSINE
AA AUROBINDO PHARMA 10MG/ML N78112 001 Mar 08, 2007 Feb NEWA
VIDEX
AA + BRISTOL MYERS SQUIBB 10MG/ML N20156 001 Oct 09, 1991 Feb CFTG

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS
IMAGENT
@ IMCOR PHARMS CO 0.92MG/VIAL;0.092MG/VIAL N21191 001 May 31, 2002 Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
BENADRYL
>A> @ MCNEIL CONS 10MG/ML N06146 001 Mar CAHN
>A> AP + 50MG/ML N06146 002 Mar CAHN
>D> @ PARKE DAVIS 10MG/ML N06146 001 Mar CAHN
>D> AP + 50MG/ML N06146 002 Mar CAHN
BENADRYL PRESERVATIVE FREE
>A> AP + MCNEIL CONS 50MG/ML N09486 001 Mar CAHN
>D> AP + PARKE DAVIS 50MG/ML N09486 001 Mar CAHN

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE
AB MURTY PHARMS 25MG N40733 001 Feb 13, 2007 Jan NEWA
AB 50MG N40733 002 Feb 13, 2007 Jan NEWA
AB 75MG N40733 003 Feb 13, 2007 Jan NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
>D> RUBEX
>D> AP BRISTOL MYERS SQUIBB 10MG/VIAL N62926 001 Apr 13, 1989 Mar DISC
>A> @ 10MG/VIAL N62926 001 Apr 13, 1989 Mar DISC

		INJECTABLE; INJECTION							
>D>		RUBEX							
>D>	AP	BRISTOL MYERS SQUIBB	50MG/VIAL	N62926	002	Apr 13, 1989	Mar	DISC	
>A>		@	50MG/VIAL	N62926	002	Apr 13, 1989	Mar	DISC	
>D>			100MG/VIAL	N62926	003	Apr 13, 1989	Mar	DISC	
>A>		@	100MG/VIAL	N62926	003	Apr 13, 1989	Mar	DISC	
		DOXYCYCLINE							
		CAPSULE; ORAL							
		DOXYCYCLINE							
	AB	RANBAXY	EQ 75MG BASE	N65053	003	Sep 10, 2003	Jan	CTEC	
		MONODOX							
	AB	OCLASSEN	EQ 75MG BASE	N50641	003	Oct 18, 2006	Jan	NEWA	
		EDETATE CALCIUM DISODIUM							
		INJECTABLE; INJECTION							
		CALCIUM DISODIUM VERSENATE							
		+ GRACEWAY	200MG/ML	N08922	001		Jan	CAHN	
		TABLET; ORAL							
		CALCIUM DISODIUM VERSENATE							
		@ GRACEWAY	500MG	N08922	002		Jan	CAHN	
		ENALAPRILAT							
		INJECTABLE; INJECTION							
		ENALAPRILAT							
>D>	AP	BEDFORD	1.25MG/ML	N75634	001	Aug 22, 2000	Mar	CRLD	
>A>	AP	+	1.25MG/ML	N75634	001	Aug 22, 2000	Mar	CRLD	
>D>		VASOTEC							
>D>	AP	+ BIOVAIL LABS INTL	1.25MG/ML	N19309	001	Feb 09, 1988	Mar	DISC	
>A>		@	1.25MG/ML	N19309	001	Feb 09, 1988	Mar	DISC	
		ERGOTAMINE TARTRATE							
		TABLET; SUBLINGUAL							
		ERGOMAR							
		+ ROSEDALE THERAPEUTIC	2MG	N87693	001	Feb 24, 1983	Jan	CAHN	
		ESTRADIOL							
		GEL, METERED; TRANSDERMAL							
		ELESTRIN							
	BX	+ BRADLEY PHARMS	0.06%	N21813	001	Dec 15, 2006	Jan	CAHN	
		TABLET; ORAL							
		ESTRADIOL							
		@ HERITAGE PHARMS INC	0.5MG	N40275	001	Dec 29, 1998	Feb	CAHN	
		@	1MG	N40275	002	Dec 29, 1998	Feb	CAHN	
		@	2MG	N40275	003	Dec 29, 1998	Feb	CAHN	
		ETHINYL ESTRADIOL; NORETHINDRONE							
		TABLET, CHEWABLE; ORAL-28							
		OVCON-35 FE							
		+ WARNER CHILCOTT	0.035MG;0.4MG	N21490	001	Nov 14, 2003	Jan	CTNA	
		ETHINYL ESTRADIOL; NORETHINDRONE ACETATE							
		TABLET; ORAL-21							
		MICROGESTIN 1.5/30							
	AB	WATSON LABS	0.03MG;1.5MG	N75548	002	Jul 30, 2003	Jan	NEWA	

TABLET; ORAL-21
MICROGESTIN 1/20

AB	WATSON LABS	0.02MG;1MG	N75647	002	Jul 30, 2003	Jan	NEWA

FAMOTIDINE

FOR SUSPENSION; ORAL
PEPCID

+	SALIX PHARMS	40MG/5ML	N19527	001	Feb 02, 1987	Feb	CAHN

FENOFIBRATE

TABLET; ORAL
TRIGLIDE

	SKYEPHARMA AG	50MG	N21350	001	May 07, 2005	Jan	CAHN
BX		160MG	N21350	002	May 07, 2005	Jan	CAHN

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
FENOLDOPAM MESYLATE

AP	SICOR PHARMS	EQ 10MG BASE/ML	N77826	001	Mar 07, 2007	Feb	NEWA

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC-12

AB	ALZA	12.5UGM/HR	N19813	005	Feb 04, 2005	Jan	CFTG

FENTANYL-100

AB	LAVIPHARM LABS	100UGM/HR	N77051	004	Aug 04, 2006	Jan	CTNA
AB	MYLAN TECHNOLOGIES	100UGM/HR	N76258	004	Jan 28, 2005	Jan	CTNA

FENTANYL-12

AB	MYLAN TECHNOLOGIES	12.5UGM/HR	N76258	005	Jan 23, 2007	Jan	NEWA

FENTANYL-25

AB	LAVIPHARM LABS	25UGM/HR	N77051	001	Aug 04, 2006	Jan	CTNA
AB	MYLAN TECHNOLOGIES	25UGM/HR	N76258	001	Jan 28, 2005	Jan	CTNA

FENTANYL-50

AB	LAVIPHARM LABS	50UGM/HR	N77051	002	Aug 04, 2006	Jan	CTNA
AB	MYLAN TECHNOLOGIES	50UGM/HR	N76258	002	Jan 28, 2005	Jan	CTNA

FENTANYL-75

AB	LAVIPHARM LABS	75UGM/HR	N77051	003	Aug 04, 2006	Jan	CTNA
AB	MYLAN TECHNOLOGIES	75UGM/HR	N76258	003	Jan 28, 2005	Jan	CTNA

FENTANYL CITRATE

TABLET; BUCCAL
FENTORA

>A>	CEPHALON	EQ 0.3MG BASE	N21947	006	Mar 02, 2007	Mar	NEWA

FINASTERIDE

TABLET; ORAL
FINASTERIDE

>A> AB	ACTAVIS TOTOWA	5MG	N77914	001	Mar 28, 2007	Mar	NEWA
AB	DR REDDYS LABS LTD	5MG	N76437	001	Feb 28, 2007	Feb	NEWA

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR

AB	GRACEWAY	50MG	N18830	004	Aug 23, 1988	Jan	CAHN
AB		100MG	N18830	001	Oct 31, 1985	Jan	CAHN

		TABLET; ORAL							
		TAMBOCOR							
	AB	+ GRACEWAY	150MG	N18830	003	Jun 03, 1988	Jan	CAHN	
		@	200MG	N18830	002	Oct 31, 1985	Jan	CAHN	
		FLUDARABINE PHOSPHATE							
		INJECTABLE; INJECTION							
		FLUDARABINE PHOSPHATE							
>A>	AP	MAYNE PHARMA USA	50MG/VIAL	N77790	001	Apr 06, 2007	Mar	NEWA	
		FLUOXETINE HYDROCHLORIDE							
		SOLUTION; ORAL							
		FLUOXETINE HYDROCHLORIDE							
	AA	SILARX	EQ 20MG BASE/5ML	N77849	001	Feb 09, 2007	Jan	NEWA	
		FLUPHENAZINE DECANOATE							
		INJECTABLE; INJECTION							
		FLUPHENAZINE DECANOATE							
	AO	+ BEDFORD	25MG/ML	N74531	001	Aug 30, 1996	Jan	CRLD	
		PROLIXIN DECANOATE							
		@ BRISTOL MYERS SQUIBB	25MG/ML	N16727	001		Jan	DISC	
		FLUPHENAZINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		FLUPHENAZINE HYDROCHLORIDE							
		+ ABRAXIS PHARM	2.5MG/ML	N89556	001	Apr 16, 1987	Jan	CRLD	
		PROLIXIN							
		@ APOTHECON	2.5MG/ML	N11751	005		Jan	DISC	
		TABLET; ORAL							
		FLUPHENAZINE HYDROCHLORIDE							
	AB	+ MYLAN	10MG	N89804	001	Aug 12, 1988	Feb	CRLD	
		PROLIXIN							
		@ APOTHECON	1MG	N11751	004		Jan	DISC	
		@	2.5MG	N11751	001		Jan	DISC	
		@	5MG	N11751	003		Jan	DISC	
		@	10MG	N11751	002		Jan	DISC	
		FOLIC ACID							
		INJECTABLE; INJECTION							
		FOLIC ACID							
		+ ABRAXIS PHARM	5MG/ML	N89202	001	Feb 18, 1986	Jan	CTEC	
		@ BEN VENUE	5MG/ML	N81066	001	Dec 29, 1993	Jan	DISC	
		FOLLITROPIN ALFA/BETA							
		INJECTABLE; SUBCUTANEOUS							
		GONAL-F							
>A>		@ EMD SERONO	37.5 IU/VIAL	N20378	003	May 25, 2000	Mar	CAHN	
>A>		@	37.5 IU/VIAL	N21765	001	Mar 25, 2004	Mar	CAHN	
>A>		@	75 IU/VIAL	N20378	001	Sep 29, 1997	Mar	CAHN	
>A>		@	150 IU/VIAL	N20378	002	Sep 29, 1997	Mar	CAHN	
>A>		@	150 IU/VIAL	N21765	003	Mar 25, 2004	Mar	CAHN	
>A>		+	450 IU/VIAL	N20378	005	Mar 26, 2004	Mar	CAHN	
>D>		@ SERONO INC	37.5 IU/VIAL	N20378	003	May 25, 2000	Mar	CAHN	
>D>		@	37.5 IU/VIAL	N21765	001	Mar 25, 2004	Mar	CAHN	
>D>		@	75 IU/VIAL	N20378	001	Sep 29, 1997	Mar	CAHN	

INJECTABLE; SUBCUTANEOUS
GONAL-F

>D>		@ SERONO INC	150 IU/VIAL	N20378	002	Sep 29, 1997	Mar	CAHN
>D>		@	150 IU/VIAL	N21765	003	Mar 25, 2004	Mar	CAHN
>D>	+		450 IU/VIAL	N20378	005	Mar 26, 2004	Mar	CAHN

GONAL-F RFF

>A>	+	EMD SERONO	75 IU/VIAL	N21765	002	Mar 25, 2004	Mar	CAHN
>D>	+	SERONO INC	75 IU/VIAL	N21765	002	Mar 25, 2004	Mar	CAHN

FORMOTEROL FUMARATE

POWDER; INHALATION
FORADIL CERTIHALER

	+	NOVARTIS	0.0085MG/INH	N21592	001	Dec 15, 2006	Jan	CRLD

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

>A>	AP	WOCKHARDT	10MG/ML	N77941	001	Mar 22, 2007	Mar	NEWA

GABAPENTIN

TABLET; ORAL
GABAPENTIN

	AB	+ IVAX PHARMS	800MG	N76017	005	Apr 29, 2005	Feb	CRLD

NEURONTIN

	AB	PFIZER PHARMS	800MG	N20882	002	Oct 09, 1998	Feb	CRLD

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

>A>	AB	PERRIGO R AND D	600MG	N78012	001	Mar 26, 2007	Mar	NEWA

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM

>D>	AP	ABRAXIS PHARM	1,000 UNITS/ML	N17979	001		Mar	DISC
>A>		@	1,000 UNITS/ML	N17979	001		Mar	DISC
>D>	AP		10,000 UNITS/ML	N17979	002		Mar	DISC
>A>		@	10,000 UNITS/ML	N17979	002		Mar	DISC
		@ WATSON LABS	1,000 UNITS/ML	N17064	002		Feb	CAHN
		@	2,500 UNITS/ML	N17064	015		Feb	CAHN
		@	3,000 UNITS/ML	N17064	016		Feb	CAHN
		@	4,000 UNITS/ML	N17064	017		Feb	CAHN
		@	5,000 UNITS/ML	N17064	003		Feb	CAHN
		@	6,000 UNITS/ML	N17064	018		Feb	CAHN
		@	7,500 UNITS/ML	N17064	019		Feb	CAHN
		@	10,000 UNITS/ML	N17064	004		Feb	CAHN
		@	20,000 UNITS/ML	N17064	005		Feb	CAHN
		@	40,000 UNITS/ML	N17064	006		Feb	CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HYDROCHLORIDE

		@ HERITAGE PHARMS INC	25MG	N86243	001		Feb	CAHN
		@	50MG	N86242	002		Feb	CAHN

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

	AB		ACTAVIS ELIZABETH	12.5MG	N40707	001	Feb 27, 2007	Feb	NEWA
>A>	AB		CARACO	25MG	N40810	001	Mar 27, 2007	Mar	NEWA
>A>	AB			50MG	N40810	002	Mar 27, 2007	Mar	NEWA
>A>	AB		EXCELLIUM	25MG	N40702	001	Mar 16, 2007	Mar	NEWA
>A>	AB			50MG	N40702	002	Mar 16, 2007	Mar	NEWA
	AB		HERITAGE PHARMS INC	25MG	N85181	001		Feb	CAHN
	AB			50MG	N85182	001		Feb	CAHN
	AB		MYLAN	12.5MG	N40770	001	Jan 23, 2007	Feb	CTEC
				12.5MG	N40770	001	Jan 23, 2007	Jan	NEWA
	AB			25MG	N40735	002	Jan 23, 2007	Jan	NEWA
	AB			50MG	N40735	003	Jan 23, 2007	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	AB		TEVA	12.5MG;7.5MG	N76980	001	Mar 07, 2007	Feb	NEWA
	AB			12.5MG;15MG	N76980	003	Mar 07, 2007	Feb	NEWA
	AB			25MG;15MG	N76980	002	Mar 07, 2007	Feb	NEWA
			UNIRETIC						
	AB		SCHWARZ PHARMA	12.5MG;7.5MG	N20729	001	Jun 27, 1997	Feb	CFTG
	AB			12.5MG;15MG	N20729	003	Feb 14, 2002	Feb	CFTG
	AB	+		25MG;15MG	N20729	002	Jun 27, 1997	Feb	CFTG

HYDROCORTISONE

TABLET; ORAL
CORTEF

>D>			PHARMACIA AND UPJOHN	5MG	N08697	003		Mar	CFTG
>A>	AB			5MG	N08697	003		Mar	CFTG
>D>				10MG	N08697	001		Mar	CFTG
>A>	AB			10MG	N08697	001		Mar	CFTG
				10MG	N08697	001		Feb	CMFD
>D>	BP	+		20MG	N08697	002		Mar	CTEC
>A>	AB	+		20MG	N08697	002		Mar	CTEC
>A>			HYDROCORTISONE						
>A>	AB		STIEFEL	5MG	N40646	001	Mar 30, 2007	Mar	NEWA
>A>	AB			10MG	N40646	002	Mar 30, 2007	Mar	NEWA
>A>	AB			20MG	N40646	003	Mar 30, 2007	Mar	NEWA

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROMORPHONE HYDROCHLORIDE

			@ WATSON LABS	10MG/ML	N74317	001	Aug 23, 1995	Feb	DISC

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HYDROCHLORIDE

			@ HOSPIRA	25MG/ML	N87416	001		Feb	DISC
			@	50MG/ML	N87546	001		Feb	DISC
			@ WATSON LABS	50MG/ML	N85779	001		Feb	DISC

TABLET; ORAL
HYDROXYZINE HYDROCHLORIDE

>A>	AB		KVK-TECH INC	10MG	N40786	001	Mar 20, 2007	Mar	NEWA
>A>	AB			25MG	N40787	001	Mar 20, 2007	Mar	NEWA
>A>	AB			50MG	N40788	001	Mar 20, 2007	Mar	NEWA

IFOSFAMIDE

INJECTABLE; INJECTION
IFSOFAMIDE

>A>		+	SICOR PHARMS	1GM/20ML (50MG/ML)	N76657	001	Apr 04, 2007	Mar	NEWA
>A>		+		3GM/60ML (50MG/ML)	N76657	002	Apr 04, 2007	Mar	NEWA

ILOPROST

SOLUTION; INHALATION
VENTAVIS

		+	ACTELION	10UGM/ML (10UGM/ML)	N21779	002	Dec 08, 2005	Jan	CAHN
		+		20UGM/2ML (10UGM/ML)	N21779	001	Dec 29, 2004	Jan	CAHN
		+	ACTELION PHARM	10UGM/ML (10UGM/ML)	N21779	002	Dec 08, 2005	Feb	CAHN
		+		20UGM/2ML (10UGM/ML)	N21779	001	Dec 29, 2004	Feb	CAHN

IMIQUIMOD

CREAM; TOPICAL
ALDARA

		+	GRACEWAY	5%	N20723	001	Feb 27, 1997	Jan	CAHN

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

			@ HERITAGE PHARMS INC	25MG	N18851	001	May 18, 1984	Feb	CAHN
			@	50MG	N18851	002	May 18, 1984	Feb	CAHN
	AB		MYLAN	25MG	N18858	001	Apr 20, 1984	Feb	CTEC
>D>	AB	+		50MG	N18858	002	Apr 20, 1984	Mar	DISC
>A>		@		50MG	N18858	002	Apr 20, 1984	Mar	DISC
>D>	AB			50MG	N70624	001	Sep 04, 1985	Mar	CRLD
>A>	AB	+		50MG	N70624	001	Sep 04, 1985	Mar	CRLD
	AB		SANDOZ	25MG	N70673	001	Apr 29, 1987	Feb	CMFD
	AB			50MG	N70674	001	Apr 29, 1987	Feb	CMFD

IRON SUCROSE

INJECTABLE; INTRAVENOUS
VENOFER

			@ LUITPOLD	EQ 50MG BASE/2.5ML(EQ 20MG BASE/ML)	N21135	002	Mar 20, 2005	Feb	DISC
			@	EQ 75MG BASE/3.75ML(EQ 20MG BASE/ML)	N21135	003	Mar 29, 2005	Feb	DISC
				EQ 200MG BASE/10ML(EQ 20MG BASE/ML)	N21135	004	Feb 09, 2007	Feb	NEWA

ISOSORBIDE DINITRATE

TABLET; ORAL
ISOSORBIDE DINITRATE

	AB		WEST WARD	30MG	N40591	001	Jan 10, 2007	Jan	NEWA

KETOPROFEN

CAPSULE; ORAL
KETOPROFEN

	AB		HERITAGE PHARMS INC	25MG	N74014	001	Jan 29, 1993	Feb	CAHN

CAPSULE; ORAL
KETOPROFEN

AB	HERITAGE PHARMS INC	50MG	N74014	002	Jan 29, 1993	Feb	CAHN
AB		75MG	N74014	003	Jan 29, 1993	Feb	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

>D>	AP	AMPHASTAR PHARM	15MG/ML	N76209	001	Jul 21, 2004	Mar	DISC
>A>		@	15MG/ML	N76209	001	Jul 21, 2004	Mar	DISC
>D>	AP		30MG/ML	N76209	002	Jul 21, 2004	Mar	DISC
>A>		@	30MG/ML	N76209	002	Jul 21, 2004	Mar	DISC
>D>	AP	APOTEX INC	30MG/ML	N75626	001	Jul 24, 2001	Mar	DISC
>A>		@	30MG/ML	N75626	001	Jul 24, 2001	Mar	DISC
>D>	AP		30MG/ML	N77201	001	Oct 14, 2005	Mar	DISC
>A>		@	30MG/ML	N77201	001	Oct 14, 2005	Mar	DISC
>D>	AP	GLAND PHARMA LTD	15MG/ML	N76722	001	Jul 27, 2004	Mar	DISC
>A>		@	15MG/ML	N76722	001	Jul 27, 2004	Mar	DISC
>D>	AP		30MG/ML	N76722	002	Jul 27, 2004	Mar	DISC
>A>		@	30MG/ML	N76722	002	Jul 27, 2004	Mar	DISC
>A>	AP	WOCKHARDT	15MG/ML	N77942	001	Mar 27, 2007	Mar	NEWA
>A>	AP		30MG/ML	N77942	002	Mar 27, 2007	Mar	NEWA
>A>	AP		30MG/ML	N77943	001	Mar 27, 2007	Mar	NEWA

>A> LAPATINIB DITOSYLATE

>A> TABLET; ORAL
>A> TYKERB

>A>	+	GLAXOSMITHKLINE	EQ 250MG BASE	N22059	001	Mar 13, 2007	Mar	NEWA

LEUCOVORIN CALCIUM

TABLET; ORAL
LEUCOVORIN CALCIUM

	@	PHARMACHEMIE	EQ 5MG BASE	N73099	001	Mar 28, 1997	Jan	DISC
	@		EQ 25MG BASE	N73101	001	Mar 28, 1997	Jan	DISC

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS
ELIGARD

	+	SANOFI AVENTIS US	7.5MG/VIAL	N21343	001	Jan 23, 2002	Jan	CAHN
	+		22.5MG/VIAL	N21379	001	Jul 24, 2002	Jan	CAHN
	+		30MG/VIAL	N21488	001	Feb 13, 2003	Jan	CAHN
	+		45MG/VIAL	N21731	001	Dec 14, 2004	Jan	CAHN

LEVOCARNITINE

SOLUTION; ORAL
>A> CARNITOR SF

>A>	AA	SIGMA TAU	1GM/10ML	N19257	002	Mar 28, 2007	Mar	NEWA

LIDOCAINE

PATCH; TOPICAL
LIDOCAINE

	+	NOVEN	46.1MG/PATCH	N20575	002	May 21, 1996	Jan	CDFR

LIDOCAINE HYDROCHLORIDE

SOLUTION; ORAL
LIDOCAINE HYDROCHLORIDE VISCOUS

AT	VINTAGE	2%	N40708	001	Feb 27, 2007	Feb	NEWA

SOLUTION; TOPICAL
LIDOCAINE HYDROCLORIDE

AT	VINTAGE	4%	N40710	001	Feb 27, 2007	Feb	NEWA

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL
VYVANSE

	NEW RIVER	30MG	N21977	001	Feb 23, 2007	Feb	NEWA
		50MG	N21977	002	Feb 23, 2007	Feb	NEWA
+		70MG	N21977	003	Feb 23, 2007	Feb	NEWA

LOVASTATIN

TABLET; ORAL
LOVASTATIN

AB	APOTEX INC	10MG	N77748	001	Feb 28, 2007	Feb	NEWA
AB		20MG	N77748	002	Feb 28, 2007	Feb	NEWA
AB		40MG	N77748	003	Feb 28, 2007	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL
ALTOPREV

	@ ANDRX LABS LLC	10MG	N21316	001	Jun 26, 2002	Feb	DISC

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL
ADVICOR

>A>	+ ABBOTT	20MG;500MG	N21249	001	Dec 17, 2001	Mar	CAHN
>A>	+	20MG;750MG	N21249	002	Dec 17, 2001	Mar	CAHN
>A>	+	20MG;1GM	N21249	003	Dec 17, 2001	Mar	CAHN
>A>	+	40MG;1GM	N21249	004	Apr 27, 2006	Mar	CAHN
>D>	+ KOS LIFE	20MG;500MG	N21249	001	Dec 17, 2001	Mar	CAHN
>D>	+	20MG;750MG	N21249	002	Dec 17, 2001	Mar	CAHN
>D>	+	20MG;1GM	N21249	003	Dec 17, 2001	Mar	CAHN
>D>	+	40MG;1GM	N21249	004	Apr 27, 2006	Mar	CAHN

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE IN PLASTIC CONTAINER

	HOSPIRA	2GM/50ML (40MG/ML)	N20309	003	Jan 26, 2007	Jan	NEWA
+		4GM/100ML (40MG/ML)	N20309	001	Jun 24, 1994	Jan	CPOT
+		4GM/50ML (80MG/ML)	N20309	002	Jun 24, 1994	Jan	CPOT

MESALAMINE

TABLET, DELAYED RELEASE; ORAL
LIALDA

+	SHIRE	1.2GM	N22000	001	Jan 16, 2007	Jan	NEWA

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

AB	TORRENT PHARMS	500MG	N77711	001	Jan 24, 2007	Jan	NEWA
AB		850MG	N77711	002	Jan 24, 2007	Jan	NEWA

TABLET; ORAL
METFORMIN HYDROCHLORIDE

AB		TORRENT PHARMS	1GM	N77711	003	Jan 24, 2007	Jan	NEWA

>A> METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

>A> TABLET; ORAL
>A> JANUMET

>A>		MERCK	500MG;EQ 50MG BASE	N22044	001	Mar 30, 2007	Mar	NEWA
>A>	+		1GM;EQ 50MG BASE	N22044	002	Mar 30, 2007	Mar	NEWA

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
CONCERTA

		JOHNSON AND JOHNSON	18MG	N21121	001	Aug 01, 2000	Feb	CAHN
			27MG	N21121	004	Apr 01, 2002	Feb	CAHN
			36MG	N21121	002	Aug 01, 2000	Feb	CAHN
	+		54MG	N21121	003	Dec 08, 2000	Feb	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

AP		BEDFORD LABS	EQ 40MG BASE/VIAL	N40662	001	Feb 21, 2007	Feb	NEWA
AP			EQ 125MG BASE/VIAL	N40641	002	Feb 21, 2007	Feb	NEWA
AP			EQ 500MG BASE/VIAL	N40641	003	Feb 21, 2007	Feb	NEWA
AP			EQ 500MG BASE/VIAL	N40709	001	Feb 21, 2007	Feb	NEWA
AP			EQ 1GM BASE/VIAL	N40641	004	Feb 21, 2007	Feb	NEWA
AP			EQ 1GM BASE/VIAL	N40709	002	Feb 21, 2007	Feb	NEWA

METRONIDAZOLE

GEL; VAGINAL
METROGEL-VAGINAL

AB	+	GRACEWAY	0.75%	N20208	001	Aug 17, 1992	Jan	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

AP		TAYLOR	EQ 1MG BASE/ML	N75494	001	Jun 30, 2000	Feb	CAHN
AP			EQ 5MG BASE/ML	N75494	002	Jun 30, 2000	Feb	CAHN

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

AP	+	HOSPIRA	EQ 1MG BASE/ML	N75857	001	Jul 22, 2002	Feb	CTNA
AP	+		EQ 5MG BASE/ML	N75857	002	Jul 22, 2002	Feb	CTNA

MITOMYCIN

INJECTABLE; INJECTION
MITOZYTREX

	+	SUPERGEN	5MG/VIAL	N50763	001	Nov 14, 2002	Jan	CTNA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION
NOVANTRONE

>A>	AP	+	EMD SERONO	EQ 20MG BASE/10ML(2MG/ML)	N19297	001	Dec 23, 1987	Mar	CAHN
>A>	AP	+		EQ 25MG BASE/12.5ML (2MG/ML)	N19297	002	Dec 23, 1987	Mar	CAHN
>A>	AP	+		EQ 30MG BASE/15ML (2MG/ML)	N19297	003	Dec 23, 1987	Mar	CAHN
>D>	AP	+	SERONO INC	EQ 20MG BASE/10ML(2MG/ML)	N19297	001	Dec 23, 1987	Mar	CAHN
>D>	AP	+		EQ 25MG BASE/12.5ML (2MG/ML)	N19297	002	Dec 23, 1987	Mar	CAHN

INJECTABLE; INJECTION
NOVANTRONE

>D>	AP	+	SERONO INC	EQ 30MG BASE/15ML (2MG/ML)	N19297	003	Dec 23, 1987	Mar	CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
AVINZA

>A>	BX		KING PHARMS	30MG	N21260	001	Mar 20, 2002	Mar	CAHN
>A>	BX			60MG	N21260	002	Mar 20, 2002	Mar	CAHN
>A>				90MG	N21260	003	Mar 20, 2002	Mar	CAHN
>A>		+		120MG	N21260	004	Mar 20, 2002	Mar	CAHN
>D>	BX		LIGAND	30MG	N21260	001	Mar 20, 2002	Mar	CAHN
>D>	BX			60MG	N21260	002	Mar 20, 2002	Mar	CAHN
>D>				90MG	N21260	003	Mar 20, 2002	Mar	CAHN
>D>		+		120MG	N21260	004	Mar 20, 2002	Mar	CAHN

KADIAN

			ALPHARMA US PHARMS	200MG	N20616	007	Feb 27, 2007	Feb	NEWA

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HYDROCHLORIDE

	AP	+	HOSPIRA	10MG/ML	N70914	001	Feb 03, 1989	Feb	CRLD
	AP	+		10MG/ML	N70915	001	Feb 03, 1989	Feb	CRLD
	AP	+		20MG/ML	N70916	001	Feb 03, 1989	Feb	CRLD
	AP	+		20MG/ML	N70918	001	Feb 03, 1989	Feb	CRLD

NUBAIN

		@	ENDO PHARMS	10MG/ML	N18024	001		Feb	DISC
		@		20MG/ML	N18024	002	May 27, 1982	Feb	DISC

NAPROXEN

TABLET; ORAL
NAPROXEN

>A>	AB		GLENMARK PHARMS INC	250MG	N78250	001	Mar 28, 2007	Mar	NEWA
>A>	AB			375MG	N78250	002	Mar 28, 2007	Mar	NEWA
>A>	AB			500MG	N78250	003	Mar 28, 2007	Mar	NEWA

NELFINAVIR MESYLATE

>D> FOR SUSPENSION; ORAL
>D> VIRACEPT

>D>		+	AGOURON	EQ 50MG BASE/SCOOPFUL	N20778	001	Mar 14, 1997	Mar	CDFR

>A> POWDER; ORAL
>A> VIRACEPT

>A>		+	AGOURON	EQ 50MG BASE/SCOOPFUL	N20778	001	Mar 14, 1997	Mar	CDFR

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS
NATRECOR

		+	ALZA CORP	1.5MG/VIAL	N20920	001	Aug 10, 2001	Jan	CAHN
		+	SCIOS	1.5MG/VIAL	N20920	001	Aug 10, 2001	Feb	CAHN

NIACIN

TABLET, EXTENDED RELEASE; ORAL
NIASPAN

>A>			@ ABBOTT	375MG	N20381	001	Jul 28, 1997	Mar	CAHN
>A>		+		500MG	N20381	002	Jul 28, 1997	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL
NIASPAN

>A>		+ ABBOTT	750MG		N20381	003	Jul 28, 1997	Mar	CAHN
>A>		+	1GM		N20381	004	Jul 28, 1997	Mar	CAHN
>D>		@ KOS LIFE	375MG		N20381	001	Jul 28, 1997	Mar	CAHN
>D>		+	500MG		N20381	002	Jul 28, 1997	Mar	CAHN
>D>		+	750MG		N20381	003	Jul 28, 1997	Mar	CAHN
>D>		+	1GM		N20381	004	Jul 28, 1997	Mar	CAHN

NIASPAN TITRATION STARTER PACK

>A>		@ ABBOTT	375MG;500MG;750MG		N20381	005	Jul 28, 1997	Mar	CAHN
>D>		@ KOS LIFE	375MG;500MG;750MG		N20381	005	Jul 28, 1997	Mar	CAHN

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
MINITRAN

	AB1	GRACEWAY	0.1MG/HR		N89771	001	Aug 30, 1996	Jan	CAHN
	AB1		0.2MG/HR		N89772	001	Aug 30, 1996	Jan	CAHN
	AB1		0.4MG/HR		N89773	001	Aug 30, 1996	Jan	CAHN
	AB1		0.6MG/HR		N89774	001	Aug 30, 1996	Jan	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

	AP	HOSPIRA	EQ 2MG BASE/ML		N77840	001	Jan 19, 2007	Jan	NEWA
>D>	AP	PHARMAFORCE	EQ 2MG BASE/ML		N77582	001	Dec 26, 2006	Mar	CAHN
>A>	AP	PLIVA	EQ 2MG BASE/ML		N77582	001	Dec 26, 2006	Mar	CAHN
>A>	AP	SPECTRUM PHARMS	EQ 2MG BASE/ML		N78180	001	Mar 26, 2007	Mar	NEWA

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

	AP	HOSPIRA	EQ 0.64MG BASE/ML		N77348	001	Feb 01, 2007	Jan	NEWA
	AP	MAYNE PHARMA USA	EQ 0.64MG BASE/ML		N76978	001	Feb 26, 2007	Feb	NEWA

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

>D>	AP	PHARMAFORCE	EQ 2MG BASE/ML		N77387	001	Dec 26, 2006	Mar	CAHN
>A>	AP	PLIVA	EQ 2MG BASE/ML		N77387	001	Dec 26, 2006	Mar	CAHN

ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

	AP	+ GLAXOSMITHKLINE	EQ 0.64MG BASE/ML		N20403	001	Jan 31, 1995	Jan	CTNA

ORPHENADRINE CITRATE

INJECTABLE; INJECTION
NORFLEX

	AP	+ GRACEWAY	30MG/ML		N13055	001		Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL
NORFLEX

		@ GRACEWAY	100MG		N12157	001		Jan	CAHN

ORPHENADRINE CITRATE

>A>	AB	ACTAVIS TOTOWA	100MG		N40284	001	Jun 19, 1998	Mar	CAHN
>D>	AB	SANDOZ	100MG		N40284	001	Jun 19, 1998	Mar	CAHN

OXANDROLONE

TABLET; ORAL
OXANDROLONE

>A>	AB	UPSHER SMITH	10MG		N78033	001	Mar 22, 2007	Mar	NEWA

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

>D>			KV PHARM	5MG	N77290	001	Dec 08, 2005	Mar	CTEC
>A>	AB			5MG	N77290	001	Dec 08, 2005	Mar	CTEC
>A>	AB		TYCO HLTHCARE	5MG	N78206	001	Mar 19, 2007	Mar	NEWA
	AB		VINTAGE PHARMS	15MG	N77712	001	Jan 31, 2007	Jan	NEWA
	AB			30MG	N77712	002	Jan 31, 2007	Jan	NEWA

ROXICODONE

	AB	+	XANODYNE PHARMS INC	15MG	N21011	001	Aug 31, 2000	Feb	CAHN
	AB			30MG	N21011	002	Aug 31, 2000	Feb	CAHN

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

	AB		ZYDUS PHARMS USA	EQ 10MG BASE	N77584	001	Mar 07, 2007	Feb	NEWA
	AB			EQ 20MG BASE	N77584	002	Mar 07, 2007	Feb	NEWA
	AB			EQ 30MG BASE	N77584	003	Mar 07, 2007	Feb	NEWA
	AB			EQ 40MG BASE	N77584	004	Mar 07, 2007	Feb	NEWA

PENTOSTATIN

INJECTABLE; INJECTION

NIPENT

>A>		+	HOSPIRA INC	10MG/VIAL	N20122	001	Oct 11, 1991	Mar	CAHN
>D>		+	MAYNE PHARMA USA	10MG/VIAL	N20122	001	Oct 11, 1991	Mar	CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

	AB		HERITAGE PHARMS INC	400MG	N74877	001	Jul 08, 1997	Feb	CAHN

>D> PERGOLIDE MESYLATE

>D> TABLET; ORAL

>D> PERGOLIDE MESYLATE

>D>	AB		IVAX PHARMS	EQ 0.05MG BASE	N76094	001	Sep 04, 2003	Mar	DISC
>A>		@		EQ 0.05MG BASE	N76094	001	Sep 04, 2003	Mar	DISC
>D>	AB			EQ 0.25MG BASE	N76094	002	Sep 04, 2003	Mar	DISC
>A>		@		EQ 0.25MG BASE	N76094	002	Sep 04, 2003	Mar	DISC
>D>	AB			EQ 1MG BASE	N76094	003	Sep 04, 2003	Mar	DISC
>A>		@		EQ 1MG BASE	N76094	003	Sep 04, 2003	Mar	DISC
>D>	AB		PAR PHARM	EQ 0.05MG BASE	N76061	001	Nov 27, 2002	Mar	DISC
>A>		@		EQ 0.05MG BASE	N76061	001	Nov 27, 2002	Mar	DISC
>D>	AB			EQ 0.25MG BASE	N76061	002	Nov 27, 2002	Mar	DISC
>A>		@		EQ 0.25MG BASE	N76061	002	Nov 27, 2002	Mar	DISC
>D>	AB			EQ 1MG BASE	N76061	003	Nov 27, 2002	Mar	DISC
>A>		@		EQ 1MG BASE	N76061	003	Nov 27, 2002	Mar	DISC

>D> PERMAX

>D>	AB		VALEANT PHARM INTL	EQ 0.05MG BASE	N19385	001	Dec 30, 1988	Mar	DISC
>A>		@		EQ 0.05MG BASE	N19385	001	Dec 30, 1988	Mar	DISC
	AB			EQ 0.05MG BASE	N19385	001	Dec 30, 1988	Jan	CAHN
>D>	AB	+		EQ 0.25MG BASE	N19385	002	Dec 30, 1988	Mar	DISC
>A>		@		EQ 0.25MG BASE	N19385	002	Dec 30, 1988	Mar	DISC
	AB	+		EQ 0.25MG BASE	N19385	002	Dec 30, 1988	Jan	CAHN
>D>	AB			EQ 1MG BASE	N19385	003	Dec 30, 1988	Mar	DISC

>D>		TABLET; ORAL							
>D>		PERMAX							
>A>		@ VALEANT PHARM INTL	EQ 1MG BASE	N19385	003	Dec 30, 1988	Mar	DISC	
	AB		EQ 1MG BASE	N19385	003	Dec 30, 1988	Jan	CAHN	
		PHENTERMINE HYDROCHLORIDE							
		CAPSULE; ORAL							
		PHENTERMINE HYDROCHLORIDE							
	AA	+ SANDOZ	30MG	N87190	001		Feb	CRLD	
	AA	TG UNITED INC	30MG	N40083	001	Mar 07, 1997	Feb	CAHN	
		PILOCARPINE HYDROCHLORIDE							
		TABLET; ORAL							
		PILOCARPINE HYDROCHLORIDE							
	AB	ROXANE	7.5MG	N76963	002	Feb 27, 2007	Feb	NEWA	
		PIPERACILLIN SODIUM							
		INJECTABLE; INJECTION							
		PIPERACILLIN							
		+ ISTITUTO BIOCHIMICO	EQ 2GM BASE/VIAL	N65114	001	Nov 14, 2003	Feb	CAHN	
		+	EQ 3GM BASE/VIAL	N65114	002	Nov 14, 2003	Feb	CAHN	
		+	EQ 4GM BASE/VIAL	N65114	003	Nov 14, 2003	Feb	CAHN	
		+	EQ 40GM BASE/VIAL	N65157	001	Jul 12, 2004	Feb	CAHN	
		PIRBUTEROL ACETATE							
		AEROSOL, METERED; INHALATION							
		MAXAIR							
		@ GRACEWAY	EQ 0.2MG BASE/INH	N19009	001	Dec 30, 1986	Jan	CAHN	
		+	EQ 0.2MG BASE/INH	N20014	001	Nov 30, 1992	Jan	CAHN	
		POLYETHYLENE GLYCOL 3350							
		FOR SOLUTION; ORAL							
		POLYETHYLENE GLYCOL 3350							
	AA	ANABOLIC LABS	17GM/SCOOPFUL	N77706	001	Sep 27, 2006	Jan	CAHN	
		PREDNICARBATE							
		OINTMENT; TOPICAL							
		DERMATOP							
	AB	+ SANOFI AVENTIS US	0.1%	N19568	001	Sep 23, 1991	Feb	CFTG	
		PREDNICARBATE							
	AB	ALTANA	0.1%	N77236	001	Mar 09, 2007	Feb	NEWA	
		PROCAINAMIDE HYDROCHLORIDE							
		CAPSULE; ORAL							
		PROCAINAMIDE HYDROCHLORIDE							
		@ IVAX PHARMS	250MG	N84604	001		Jan	DISC	
		@	375MG	N84595	001		Jan	DISC	
		@	500MG	N84606	001		Jan	DISC	
		@ WATSON LABS	250MG	N83287	001		Jan	DISC	
		@	375MG	N84403	001		Jan	DISC	
		@	500MG	N84280	001		Jan	DISC	
		PRONESTYL							
		@ APOTHECON	250MG	N07335	001		Jan	DISC	
		@	375MG	N07335	004		Jan	DISC	
		@	500MG	N07335	003		Jan	DISC	

		TABLET, EXTENDED RELEASE; ORAL							
		PRONESTYL-SR							
		@ APOTHECON	500MG	N87361	001		Jan	DISC	
		PROCHLORPERAZINE							
		SUPPOSITORY; RECTAL							
		COMPAZINE							
		@ GLAXOSMITHKLINE	25MG	N11127	002		Feb	DISC	
		PROCHLORPERAZINE							
	AB	+ G AND W LABS	25MG	N40058	001	Nov 24, 1993	Feb	CRLD	
		PROCHLORPERAZINE EDISYLATE							
		INJECTABLE; INJECTION							
		COMPAZINE							
		@ GLAXOSMITHKLINE	EQ 5MG BASE/ML	N10742	002		Feb	DISC	
		PROCHLORPERAZINE							
		@ BAXTER HLTHCARE	EQ 5MG BASE/ML	N87759	001	Oct 01, 1982	Feb	DISC	
		PROCHLORPERAZINE EDISYLATE							
	AP	+ BAXTER HLTHCARE	EQ 5MG BASE/ML	N89903	001	Aug 29, 1989	Feb	CRLD	
		@ HOSPIRA	EQ 5MG BASE/ML	N89703	001	Apr 07, 1988	Feb	DISC	
		@ WATSON LABS	EQ 5MG BASE/ML	N89530	001	Jul 08, 1987	Feb	DISC	
		PROCHLORPERAZINE MALEATE							
		CAPSULE, EXTENDED RELEASE; ORAL							
		COMPAZINE							
		@ GLAXOSMITHKLINE	EQ 15MG BASE	N21019	002	Oct 06, 1999	Jan	DISC	
		TABLET; ORAL							
		COMPAZINE							
		@ GLAXOSMITHKLINE	EQ 5MG BASE	N10571	001		Feb	DISC	
		@	EQ 10MG BASE	N10571	002		Feb	DISC	
		@	EQ 25MG BASE	N10571	003		Feb	DISC	
		PROCHLORPERAZINE MALEATE							
	AB	+ SANDOZ	EQ 10MG BASE	N40101	002	Jul 19, 1996	Feb	CRLD	
		@	EQ 25MG BASE	N40101	003	Jul 19, 1996	Feb	DISC	
		PROMETHAZINE HYDROCHLORIDE							
		SYRUP; ORAL							
		PROMETHAZINE HYDROCHLORIDE							
>A>	AA	TARO	6.25MG/5ML	N40718	001	Apr 04, 2007	Mar	NEWA	
		PROPOXYPHENE HYDROCHLORIDE							
		CAPSULE; ORAL							
		DOLENE							
		@ HERITAGE PHARMS INC	65MG	N80530	001		Feb	CAHN	
		PROPRANOLOL HYDROCHLORIDE							
		CAPSULE, EXTENDED RELEASE; ORAL							
		INDERAL LA							
	AB	WYETH PHARMS INC	60MG	N18553	004	Mar 18, 1987	Jan	CTEC	
	AB		80MG	N18553	002	Apr 19, 1983	Jan	CTEC	
	AB		120MG	N18553	003	Apr 19, 1983	Jan	CTEC	
	AB	+	160MG	N18553	001	Apr 19, 1983	Jan	CTEC	
		PROPRANOLOL HYDROCHLORIDE							
	AB	MYLAN	60MG	N78022	001	Feb 15, 2007	Feb	NEWA	
	AB		80MG	N78022	002	Feb 15, 2007	Feb	NEWA	

		CAPSULE, EXTENDED RELEASE; ORAL							
		PROPRANOLOL HYDROCHLORIDE							
	AB	MYLAN	120MG	N78022	003	Feb 15, 2007	Feb	NEWA	
	AB		160MG	N78022	004	Feb 15, 2007	Feb	NEWA	
	AB	PAR PHARM	60MG	N78065	001	Jan 26, 2007	Jan	NEWA	
	AB		80MG	N78065	002	Jan 26, 2007	Jan	NEWA	
	AB		120MG	N78065	003	Jan 26, 2007	Jan	NEWA	
	AB		160MG	N78065	004	Jan 26, 2007	Jan	NEWA	
		TABLET; ORAL							
		INDERAL							
		@ WYETH PHARMS INC	10MG	N16418	001		Jan	DISC	
		@	20MG	N16418	003		Jan	DISC	
		PYRIDOXINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		PYRIDOXINE HYDROCHLORIDE							
	+	ABRAXIS PHARM	100MG/ML	N80618	001		Jan	CRLD	
		@ WATSON LABS	100MG/ML	N80572	001		Jan	DISC	
		QUINIDINE SULFATE							
		TABLET; ORAL							
		QUINIDINE SULFATE							
>D>	AB	WATSON LABS	200MG	N83288	001		Mar	DISC	
>A>		@	200MG	N83288	001		Mar	DISC	
		RABEPRAZOLE SODIUM							
		TABLET, DELAYED RELEASE; ORAL							
		ACIPHEX							
	AB	+ EISAI MEDCL RES	20MG	N20973	002	Aug 19, 1999	Feb	CFTG	
		RABEPRAZOLE SODIUM							
	AB	TEVA	20MG	N76822	001	Feb 21, 2007	Feb	NEWA	
		RAMIPRIL							
		CAPSULE; ORAL							
		ALTACE							
		KING PHARMS	1.25MG	N19901	001	Jan 28, 1991	Jan	CTEC	
			2.5MG	N19901	002	Jan 28, 1991	Jan	CTEC	
			5MG	N19901	003	Jan 28, 1991	Jan	CTEC	
	+		10MG	N19901	004	Jan 28, 1991	Jan	CTEC	
		RAMIPRIL							
		@ COBALT	1.25MG	N76549	001	Oct 24, 2005	Jan	DISC	
		@	2.5MG	N76549	002	Oct 24, 2005	Jan	DISC	
		@	5MG	N76549	003	Oct 24, 2005	Jan	DISC	
		@	10MG	N76549	004	Oct 24, 2005	Jan	DISC	
		TABLET; ORAL							
		ALTACE							
		COBALT	1.25MG	N22021	001	Feb 27, 2007	Feb	NEWA	
			2.5MG	N22021	002	Feb 27, 2007	Feb	NEWA	
			5MG	N22021	003	Feb 27, 2007	Feb	NEWA	
	+		10MG	N22021	004	Feb 27, 2007	Feb	NEWA	
		RANITIDINE HYDROCHLORIDE							
		SYRUP; ORAL							
		RANITIDINE HYDROCHLORIDE							
	AA	ALPHARMA US PHARMS	EQ 15MG BASE/ML	N76124	001	Feb 21, 2007	Feb	NEWA	

SYRUP; ORAL
ZANTAC

AA	+	GLAXOSMITHKLINE	EQ 15MG BASE/ML	N19675	001	Dec 30, 1988	Feb	CFTG

RIBAVIRIN

TABLET; ORAL
RIBAVIRIN

>D>		THREE RIVERS PHARMS	400MG	N77456	002	Dec 05, 2005	Mar	CTEC
>A>	AB		400MG	N77456	002	Dec 05, 2005	Mar	CTEC
>D>	+		600MG	N77456	003	Dec 05, 2005	Mar	CTEC
>A>	AB	+	600MG	N77456	003	Dec 05, 2005	Mar	CTEC
>A>	AB	ZYDUS PHARMS USA	400MG	N77094	002	Mar 16, 2007	Mar	NEWA
>A>	AB		600MG	N77094	003	Mar 16, 2007	Mar	NEWA

SERMORELIN ACETATE

INJECTABLE; INJECTION
GEREF

	+	EMD SERONO	EQ 0.05MG BASE/AMP	N19863	001	Dec 28, 1990	Feb	CAHN
	@		EQ 0.5MG BASE/VIAL	N20443	001	Sep 26, 1997	Feb	CAHN
	@		EQ 1MG BASE/VIAL	N20443	002	Sep 26, 1997	Feb	CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL
SERTRALINE HYDROCHLORIDE

AA		RANBAXY	EQ 20MG BASE/ML	N78053	001	Feb 05, 2007	Feb	CTEC
AB			EQ 20MG BASE/ML	N78053	001	Feb 05, 2007	Jan	NEWA
AA		ROXANE	EQ 20MG BASE/ML	N76934	001	Jun 30, 2006	Feb	CTEC

ZOLOFT

AA	+	PFIZER	EQ 20MG BASE/ML	N20990	001	Dec 07, 1999	Feb	CTEC

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 25MG BASE	N77345	001	Feb 06, 2007	Jan	NEWA
AB			EQ 50MG BASE	N77345	002	Feb 06, 2007	Jan	NEWA
AB			EQ 100MG BASE	N77345	003	Feb 06, 2007	Jan	NEWA
AB		APOTEX INC	EQ 25MG BASE	N76882	001	Feb 06, 2007	Jan	NEWA
AB			EQ 50MG BASE	N76882	002	Feb 06, 2007	Jan	NEWA
AB			EQ 100MG BASE	N76882	003	Feb 06, 2007	Jan	NEWA
AB		AUROBINDO PHARMA	EQ 25MG BASE	N77206	001	Feb 06, 2007	Jan	NEWA
AB			EQ 50MG BASE	N77206	002	Feb 06, 2007	Jan	NEWA
AB			EQ 100MG BASE	N77206	003	Feb 06, 2007	Jan	NEWA
AB		COBALT	EQ 25MG BASE	N77663	001	Feb 06, 2007	Jan	NEWA
AB			EQ 50MG BASE	N77663	002	Feb 06, 2007	Jan	NEWA
AB			EQ 100MG BASE	N77663	003	Feb 06, 2007	Jan	NEWA
>A>	AB	GENPHARM	EQ 25MG BASE	N76540	001	Mar 20, 2007	Mar	NEWA
>A>	AB		EQ 50MG BASE	N76540	002	Mar 20, 2007	Mar	NEWA
>A>	AB		EQ 100MG BASE	N76540	003	Mar 20, 2007	Mar	NEWA
AB		INVAGEN PHARMS	EQ 25MG BASE	N77397	001	Feb 06, 2007	Jan	NEWA
AB			EQ 50MG BASE	N77397	002	Feb 06, 2007	Jan	NEWA
AB			EQ 100MG BASE	N77397	003	Feb 06, 2007	Jan	NEWA
AB		LUPIN	EQ 25MG BASE	N77670	001	Feb 06, 2007	Jan	NEWA
AB			EQ 50MG BASE	N77670	002	Feb 06, 2007	Jan	NEWA
AB			EQ 100MG BASE	N77670	003	Feb 06, 2007	Jan	NEWA
AB		MUTUAL PHARM	EQ 25MG BASE	N77818	001	Feb 06, 2007	Jan	NEWA
AB			EQ 50MG BASE	N77818	002	Feb 06, 2007	Jan	NEWA
AB			EQ 100MG BASE	N77818	003	Feb 06, 2007	Jan	NEWA
AB		MYLAN	EQ 25MG BASE	N76671	001	Feb 06, 2007	Jan	NEWA

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

AB	MYLAN	EQ 50MG BASE	N76671	002	Feb 06, 2007	Jan	NEWA
AB		EQ 100MG BASE	N76671	003	Feb 06, 2007	Jan	NEWA
AB	PLIVA HRVATSKA DOO	EQ 25MG BASE	N77299	001	Feb 06, 2007	Jan	NEWA
AB		EQ 50MG BASE	N77299	002	Feb 06, 2007	Jan	NEWA
AB		EQ 100MG BASE	N77299	003	Feb 06, 2007	Jan	NEWA
AB	RANBAXY	EQ 25MG BASE	N77977	001	Feb 06, 2007	Jan	NEWA
AB		EQ 50MG BASE	N77977	002	Feb 06, 2007	Jan	NEWA
AB		EQ 100MG BASE	N77977	003	Feb 06, 2007	Jan	NEWA
		EQ 150MG BASE	N77977	004	Feb 06, 2007	Jan	NEWA
		EQ 200MG BASE	N77977	005	Feb 06, 2007	Jan	NEWA
AB	ROXANE	EQ 25MG BASE	N76881	001	Feb 06, 2007	Jan	NEWA
AB		EQ 50MG BASE	N76881	002	Feb 06, 2007	Jan	NEWA
AB		EQ 100MG BASE	N76881	003	Feb 06, 2007	Jan	NEWA
AB	SANDOZ	EQ 25MG BASE	N77713	001	Feb 06, 2007	Jan	NEWA
AB		EQ 50MG BASE	N77713	002	Feb 06, 2007	Jan	NEWA
AB		EQ 100MG BASE	N77713	003	Feb 06, 2007	Jan	NEWA
AB	SUN PHARM INDS (IN)	EQ 25MG BASE	N78108	001	Feb 06, 2007	Jan	NEWA
AB		EQ 50MG BASE	N78108	002	Feb 06, 2007	Jan	NEWA
AB		EQ 100MG BASE	N78108	003	Feb 06, 2007	Jan	NEWA
AB	TORRENT PHARMS	EQ 25MG BASE	N77765	001	Feb 06, 2007	Jan	NEWA
AB		EQ 50MG BASE	N77765	002	Feb 06, 2007	Jan	NEWA
AB		EQ 100MG BASE	N77765	003	Feb 06, 2007	Jan	NEWA
AB	WATSON LABS	EQ 25MG BASE	N77162	001	Feb 06, 2007	Jan	NEWA
AB		EQ 50MG BASE	N77162	002	Feb 06, 2007	Jan	NEWA
AB		EQ 100MG BASE	N77162	003	Feb 06, 2007	Jan	NEWA
AB	ZYDUS PHARMS USA	EQ 25MG BASE	N77106	001	Feb 06, 2007	Jan	NEWA
AB		EQ 50MG BASE	N77106	002	Feb 06, 2007	Jan	NEWA
AB		EQ 100MG BASE	N77106	003	Feb 06, 2007	Jan	NEWA

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE IN PLASTIC CONTAINER

+	HOSPIRA	5MEQ/ML	N18947	001	Sep 05, 1984	Feb	CRLD

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
SAIZEN

BX	EMD SERONO	4MG/VIAL	N19764	005	Jan 16, 2007	Feb	CAHN
BX		5MG/VIAL	N19764	002	Oct 08, 1996	Feb	CAHN
	@	6MG/VIAL	N19764	001	Oct 08, 1996	Feb	CAHN
+		8.8MG/VIAL	N19764	003	Aug 29, 2000	Feb	CAHN
BX	SERONO	4MG/VIAL	N19764	005	Jan 16, 2007	Jan	NEWA

SEROSTIM

BX	EMD SERONO	4MG/VIAL	N20604	003	Jul 25, 1997	Feb	CAHN
BX		5MG/VIAL	N20604	002	Aug 23, 1996	Feb	CAHN
BX		6MG/VIAL	N20604	001	Aug 23, 1996	Feb	CAHN
	@	8.8MG/VIAL	N20604	004	Sep 06, 2001	Feb	CAHN

INJECTABLE; SUBCUTANEOUS
SEROSTIM LQ

	@ EMD SERONO	6MG/0.5ML	N20604	005	Feb 11, 2005	Feb	CAHN

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

AB2		MYLAN	80MG	N77616	001	Feb 07, 2007	Jan	NEWA
AB2			120MG	N77616	002	Feb 07, 2007	Jan	NEWA
AB2			160MG	N77616	003	Feb 07, 2007	Jan	NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

		@ MUTUAL PHARM	80MG/ML;16MG/ML	N18374	001		Feb	DISC

SUSPENSION; ORAL

BACTRIM PEDIATRIC

		@ MUTUAL PHARM	200MG/5ML;40MG/5ML	N17560	002		Feb	DISC

SEPTRA

		@ MONARCH PHARMS	200MG/5ML;40MG/5ML	N17598	001		Feb	DISC

SEPTRA GRAPE

		@ MONARCH PHARMS	200MG/5ML;40MG/5ML	N17598	002	Feb 12, 1986	Feb	DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM

		@ TEVA	200MG/5ML;40MG/5ML	N18812	002	Jun 10, 1983	Feb	DISC
		@	200MG/5ML;40MG/5ML	N18812	001	Jan 28, 1983	Feb	DISC
AB	+	TEVA PHARMS	200MG/5ML;40MG/5ML	N77612	001	Nov 13, 2006	Feb	CRLD
AB		VINTAGE	200MG/5ML;40MG/5ML	N77785	001	Jan 24, 2007	Jan	NEWA

SULFATRIM

>D>								
>D>	AB	ACTAVIS MID ATLANTIC	200MG/5ML;40MG/5ML	N18615	002	Jan 07, 1983	Mar	DISC
>A>		@	200MG/5ML;40MG/5ML	N18615	002	Jan 07, 1983	Mar	DISC

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		VINTAGE	400MG;80MG	N78060	002	Jan 25, 2007	Jan	NEWA
AB			800MG;160MG	N78060	001	Jan 25, 2007	Jan	NEWA

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

		@ HERITAGE PHARMS INC	500MG	N80197	001		Feb	CAHN

SULINDAC

TABLET; ORAL

SULINDAC

		@ HERITAGE PHARMS INC	150MG	N73262	002	Sep 06, 1991	Feb	CAHN
		@	200MG	N73262	001	Sep 06, 1991	Feb	CAHN

TAMOXIFEN CITRATE

TABLET; ORAL

>D>		NOLVADEX						
>D>	AB	ASTRAZENECA	EQ 10MG BASE	N17970	001		Mar	DISC
>A>		@	EQ 10MG BASE	N17970	001		Mar	DISC
>D>	AB	+	EQ 20MG BASE	N17970	002	Mar 21, 1994	Mar	DISC
>A>		@	EQ 20MG BASE	N17970	002	Mar 21, 1994	Mar	DISC

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

AP	+	DRAXIMAGE	N/A	N18035	001		Jan	CTNA

INJECTABLE; INJECTION
DRAXIMAGE MDP-25
\+ DRAXIMAGE N/A N18035 002 Feb 27, 2004 Jan NEWA

>D> TEGASEROD MALEATE

>D> TABLET; ORAL
>D> ZELNORM
>D> NOVARTIS EQ 2MG BASE N21200 001 Jul 24, 2002 Mar DISC
>A> @ EQ 2MG BASE N21200 001 Jul 24, 2002 Mar DISC
>D> + EQ 6MG BASE N21200 002 Jul 24, 2002 Mar DISC
>A> @ EQ 6MG BASE N21200 002 Jul 24, 2002 Mar DISC

TERCONAZOLE

SUPPOSITORY; VAGINAL
TERCONAZOLE
AB TARO 80MG N77553 001 Mar 09, 2007 Feb NEWA

THALIDOMIDE

CAPSULE; ORAL
THALOMID
CELGENE 150MG N20785 004 Jan 10, 2007 Jan NEWA

THEOPHYLLINE

TABLET; ORAL
QUIBRON-T
@ MONARCH PHARMS 300MG N88656 001 Aug 22, 1985 Feb DISC
THEOLAIR
>D> + 3M 125MG N86399 001 Mar CAHN
>D> + 250MG N86399 002 Mar CAHN
>A> + GRACEWAY 125MG N86399 001 Mar CAHN
>A> + 250MG N86399 002 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL
QUIBRON-T/SR
@ MONARCH PHARMS 300MG N87563 001 Jun 21, 1983 Feb DISC

TOLCAPONE

TABLET; ORAL
TASMAR
VALEANT PHARM INTL 100MG N20697 001 Jan 29, 1998 Jan CAHN
\+ 200MG N20697 002 Jan 29, 1998 Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ULTRAM ER
BIOVAIL LABS INTL 100MG N21692 001 Sep 08, 2005 Feb CTNA
200MG N21692 002 Sep 08, 2005 Feb CTNA
\+ 300MG N21692 003 Sep 08, 2005 Feb CTNA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HYDROCHLORIDE
>A> AB APOTEX 50MG N71258 001 Mar 25, 1987 Mar CAHN
>D> AB BARR 50MG N71258 001 Mar 25, 1987 Mar CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

KENALOG

>D>	AT	+	APOTHECON	0.5%	N83943	001		Mar	DISC
>A>		@		0.5%	N83943	001		Mar	DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

	AB		RANBAXY	EQ 500MG BASE	N76588	001	Jan 31, 2007	Jan	NEWA
	AB			EQ 1GM BASE	N76588	002	Jan 31, 2007	Jan	NEWA

VALTREX

	AB		GLAXOSMITHKLINE	EQ 500MG BASE	N20487	001	Jun 23, 1995	Jan	CFTG
	AB	+		EQ 1GM BASE	N20487	002	Jun 23, 1995	Jan	CFTG

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPTIN

		@	FSC	2.5MG/ML	N18485	001		Feb	DISC

VERAPAMIL HYDROCHLORIDE

		@	LUITPOLD	2.5MG/ML	N70225	001	Nov 12, 1985	Feb	DISC
	AP	+		2.5MG/ML	N70617	001	Nov 12, 1985	Feb	CRLD

TABLET; ORAL

CALAN

	AB	+	GD SEARLE LLC	120MG	N18817	002	Sep 10, 1984	Feb	CRLD

ISOPTIN

		@	FSC	40MG	N18593	003	Nov 23, 1987	Feb	DISC
		@		80MG	N18593	001	Mar 08, 1982	Feb	DISC
		@		120MG	N18593	002	Mar 08, 1982	Feb	DISC

VERAPAMIL HYDROCHLORIDE

		@	HERITAGE PHARMS INC	80MG	N71880	001	Apr 05, 1988	Feb	CAHN
		@		120MG	N71881	001	Apr 05, 1988	Feb	CAHN

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

	AB		COREPHARMA	25MG	N77876	001	Feb 21, 2007	Feb	NEWA
	AB			50MG	N77876	002	Feb 21, 2007	Feb	NEWA
	AB			100MG	N77876	003	Feb 21, 2007	Feb	NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

+	ENTURIA INC	2%;70% (10.5ML)	N20832	004	Aug 20, 2003	Jan	CAHN
+		2%;70% (3ML)	N20832	001	Jul 14, 2000	Jan	CAHN
+		2%;70% (26ML)	N20832	006	Nov 21, 2006	Jan	CAHN

CHLORAPREP ONE-STEP FREPP

+	ENTURIA INC	2%;70% (1.5ML)	N20832	003	Apr 26, 2002	Jan	CAHN

CHLORAPREP WITH TINT

+	ENTURIA INC	2%;70% (3ML)	N20832	007	Oct 10, 2006	Feb	NEWA
+		2%;70% (26ML)	N20832	002	May 03, 2005	Jan	CAHN
+		2%;70% (10.5ML)	N20832	005	Apr 03, 2006	Jan	CAHN

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+	ENTURIA INC	2%;70% (0.67ML)	N21555	001	Oct 07, 2002	Jan	CAHN

CHLORAPREP SINGLE SWABSTICK

+	ENTURIA INC	2%;70% (1.75ML)	N21555	002	May 10, 2005	Jan	CAHN

DOXYLAMINE SUCCINATE

TABLET; ORAL

UNISOM

+	CHATTEM	25MG	N18066	001		Feb	CAHN
+	MCNEIL CONS	25MG	N18066	001		Jan	CAHN

FAMOTIDINE

TABLET, CHEWABLE; ORAL

FAMOTIDINE

>D>		PERRIGO	10MG	N75715	001	Aug 22, 2003	Mar	CRLD
>A>	+		10MG	N75715	001	Aug 22, 2003	Mar	CRLD
>D>		PEPCID AC						
>D>	+	MERCK	10MG	N20801	001	Sep 24, 1998	Mar	DISC
>A>	@		10MG	N20801	001	Sep 24, 1998	Mar	DISC

IBUPROFEN

CAPSULE; ORAL

ADVIL LIQUI-GELS

+	WYETH CONS	EQ 200MG FREE ACID AND POTASSIUM SALT	N20402	001	Apr 20, 1995	Jan	CAIN

ADVIL MIGRAINE LIQUI-GELS

+	WYETH CONS	EQ 200MG FREE ACID AND POTASSIUM SALT	N20402	002	Mar 16, 2000	Jan	CAIN

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

+	BAUSCH AND LOMB	EQ 0.025% BASE	N21996	001	Dec 01, 2006	Jan	CAHN

LOPERAMIDE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL

IMODIUM A-D EZ CHEWS

+	MCNEIL	2MG	N20448	001	Jul 24, 1997	Jan	CTNA

NONOXYNOL-9

SPONGE; VAGINAL
TODAY

+	ALLENDALE PHARMS	1GM		N18683	001	Apr 01, 1983	Feb	CMFD

ORLISTAT

CAPSULE; ORAL
ALLI

+	GLAXOSMITHKLINE CONS	60MG		N21887	001	Feb 07, 2007	Feb	NEWA

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
SUDAFED 12 HOUR

>A>	+	MCNEIL CONS	120MG	N73585	001	Oct 31, 1991	Mar	CAHN
>D>	+	WARNER LAMBERT	120MG	N73585	001	Oct 31, 1991	Mar	CAHN

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL
ZANTAC 75

@	BOEHRINGER INGELHEIM	EQ 75MG BASE		N20745	001	Feb 26, 1998	Feb	CAHN

TABLET; ORAL
ZANTAC 150

+	BOEHRINGER INGELHEIM	EQ 150MG BASE		N21698	001	Aug 31, 2004	Jan	CAHN

ZANTAC 75

	BOEHRINGER INGELHEIM	EQ 75MG BASE		N20520	001	Dec 19, 1995	Jan	CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2007

NO MARCH 2007 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MARCH 2007 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALBUTEROL SULFATE - VENTOLIN HFA							
020983 001	6558651	Dec 19, 2016		DP			
	6743413	Jun 01, 2021		DP	U-716		
ALISKIREN HEMIFUMARATE - TEKTURNA							
021985 001						>A> NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE - TEKTURNA							
021985 002						>A> NCE	Mar 05, 2012
ANIDULAFUNGIN - ERAXIS							
021632 002	5965525	Oct 12, 2016	DS	DP	U-540		
	6384013	Mar 19, 2012	DS				
	6743777	Mar 19, 2012		DP	U-540		
	6960564	Apr 12, 2021		DP	U-540		
ARFORMOTEROL TARTRATE - BROVANA							
021912 001	5795564	Apr 03, 2012			U-793		
	6068833	Apr 03, 2012			U-793		
	6589508	Apr 03, 2012			U-793		
	6866839	Apr 03, 2012			U-793		
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP							
021881 001	7169381	Sep 01, 2024	DS	DP			
ATORVASTATIN CALCIUM - LIPITOR							
020702 001						I-523	Mar 02, 2010
ATORVASTATIN CALCIUM - LIPITOR							
020702 002						I-523	Mar 02, 2010
ATORVASTATIN CALCIUM - LIPITOR							
020702 003						I-523	Mar 02, 2010
ATORVASTATIN CALCIUM - LIPITOR							
020702 004						I-523	Mar 02, 2010
AVOBENZONE; ECAMSULE; OCTOCRYLENE - CAPITAL SOLEIL 15							
021501 001						NC	Jul 21, 2009
						NP	Oct 02, 2009
AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE - ANTHELIOS 20							
021471 001						NC	Oct 05, 2009
BALSALAZIDE DISODIUM - COLAZAL							
020610 001						ODE	Dec 20, 2013
						>A> PED	Jun 20, 2014
BORTEZOMIB - VELCADE							
021602 001	>A> 5780454	May 03, 2017		DP			
BOSENTAN - TRACLEER							
021290 001						M-64	Feb 15, 2010
BOSENTAN - TRACLEER							
021290 002						M-64	Feb 15, 2010
BUDESONIDE - PULMICORT RESPULES							
020929 001	6899099	Dec 23, 2018			U-645		
BUDESONIDE - PULMICORT RESPULES							
020929 002	6899099	Dec 23, 2018			U-645		
BUPROPION HYDROCHLORIDE - BUPROPION HYDROCHLORIDE							
077284 002						PC	Jun 12, 2007
BUPROPION HYDROCHLORIDE - BUPROPION HYDROCHLORIDE							
077415 002						PC	Jun 12, 2007
CARVEDILOL - COREG							
020297 001						>A> M-61	Feb 23, 2010
						>A> PED	Aug 23, 2010
CARVEDILOL - COREG							
020297 002						>A> M-61	Feb 23, 2010
						>A> PED	Aug 23, 2010

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARVEDILOL - COREG								
020297 003							>A> M-61	Feb 23, 2010
							>A> PED	Aug 23, 2010
CARVEDILOL - COREG								
020297 004							>A> M-61	Feb 23, 2010
							>A> PED	Aug 23, 2010
CELECOXIB - CELEBREX								
020998 004		5466823	Nov 30, 2013	DS			I-466	Jul 29, 2008
		5466823*PED	May 30, 2014				NPP	Dec 15, 2009
		5563165	Nov 30, 2013		DP		PED	Jun 15, 2010
		5563165*PED	May 30, 2014				PED	Jan 29, 2009
		5760068	Jun 02, 2015			U-672		
		5760068*PED	Dec 02, 2015					
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP								
020832 006		6991394	Jan 31, 2024		DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
020832 002		6991394	Jan 31, 2024		DP			
CICLESONIDE - OMNARIS								
022004 001		5482934	Jan 09, 2013	DS	DP	U-557		
		6767901	Oct 21, 2020		DP			
		6939559	Apr 21, 2019		DP			
CLOBETASOL PROPIONATE - OLUX E								
022013 001		6730288	Sep 08, 2019		DP		NP	Jan 12, 2010
		7029659	Sep 08, 2019		DP			
CLOZAPINE - FAZACLO ODT								
021590 001	>A>	5178878	Jan 12, 2010		DP			
CLOZAPINE - FAZACLO ODT								
021590 002	>A>	5178878	Jan 12, 2010		DP			
CLOZAPINE - FAZACLO ODT								
021590 003	>A>	5178878	Jan 12, 2010		DP			
COLESTIPOL HYDROCHLORIDE - COLESTIPOL HYDROCHLORIDE								
077510 001							PC	Jun 12, 2007
CONIVAPTAN HYDROCHLORIDE - VAPRISOL								
021697 001							>A> I-526	Feb 28, 2010
CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX								
021777 001							NDF	Feb 01, 2010
CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX								
021777 002							NDF	Feb 01, 2010
DASATINIB - SPRYCEL								
021986 001		7153856	Apr 28, 2020			U-780		
DASATINIB - SPRYCEL								
021986 002		7153856	Apr 28, 2020			U-780		
DASATINIB - SPRYCEL								
021986 003		7153856	Apr 28, 2020			U-780		
DECITABINE - DACOGEN								
021790 001							ODE	May 02, 2013
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR								
021802 004		5837284	Dec 04, 2015		DP			
		5908850	Dec 04, 2015			U-678		
		6228398	Nov 01, 2019		DP	U-676		
		6528530	Dec 04, 2015		DP			
		6635284	Dec 04, 2015		DP	U-677		
		6730325	Nov 01, 2019		DP	U-676		
DICLOFENAC EPOLAMINE - FLECTOR								
021234 001		4948805	Nov 09, 2007	DS			NE	Jan 31, 2010
		5607690	Apr 13, 2014		DP		NDF	Jan 31, 2010

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DROSPIRENONE; ETHINYL ESTRADIOL - YAZ								
021676 001		7163931	Dec 20, 2021			U-1	I-522	Jan 26, 2010
DULOXETINE HYDROCHLORIDE - CYMBALTA								
021427 001	**>A>**	5023269	Jun 11, 2008	DS	DP	U-795	I-524	Feb 23, 2010
	>A>	5023269	Jun 11, 2008	DS	DP	U-799		
	>A>	5023269	Jun 11, 2008	DS	DP	U-797		
	>A>	5023269	Jun 11, 2008	DS	DP	U-796		
	>A>	5023269	Jun 11, 2008	DS	DP	U-605		
DULOXETINE HYDROCHLORIDE - CYMBALTA								
021427 002	**>A>**	5023269	Jun 11, 2008	DS	DP	U-797	I-524	Feb 23, 2010
	>A>	5023269	Jun 11, 2008	DS	DP	U-799		
	>A>	5023269	Jun 11, 2008	DS	DP	U-796		
	>A>	5023269	Jun 11, 2008	DS	DP	U-795		
	>A>	5023269	Jun 11, 2008	DS	DP	U-605		
DULOXETINE HYDROCHLORIDE - CYMBALTA								
021427 004	**>A>**	5023269	Jun 11, 2008	DS	DP	U-795	I-524	Feb 23, 2010
	>A>	5023269	Jun 11, 2008	DS	DP	U-797		
	>A>	5023269	Jun 11, 2008	DS	DP	U-799		
	>A>	5023269	Jun 11, 2008	DS	DP	U-796		
	>A>	5023269	Jun 11, 2008	DS	DP	U-605		
EMTRICITABINE - EMTRIVA								
021500 001		5210085	May 11, 2010			U-257		
		5814639	Sep 29, 2015	DS	DP			
		5914331	Sep 29, 2015	DS				
ENTECAVIR - BARACLUDE								
021798 001	**>A>**	5908638	Jul 26, 2015		DP			
EPLERENONE - INSPRA								
021437 001	**>A>**	4559332	Aug 11, 2007	DS	DP	U-537		
		7157101	Dec 08, 2019		DP	U-664		
EPLERENONE - INSPRA								
021437 002	**>A>**	4559332	Aug 11, 2007	DS	DP	U-537		
		7157101	Dec 08, 2019		DP	U-664		
EPLERENONE - INSPRA								
021437 003	**>A>**	4559332	Aug 11, 2007	DS	DP	U-537		
		7157101	Dec 08, 2019		DP	U-664		
ERTAPENEM SODIUM - INVANZ								
021337 001	**>A>**	5478820	Nov 21, 2015	DS	DP	U-160		
	>A>	5478820*PED	May 21, 2016					
ESTRADIOL; NORETHINDRONE ACETATE - ACTIVELLA								
020907 002							D-104	Dec 28, 2009
							I-525	Dec 29, 2009
ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN								
020992 001	**>A>**	5908638	Jul 26, 2015		DP			
FENTANYL CITRATE - ACTIQ								
020747 001							M-63	Feb 06, 2010
FENTANYL CITRATE - ACTIQ								
020747 002							M-63	Feb 06, 2010
FENTANYL CITRATE - ACTIQ								
020747 003							M-63	Feb 06, 2010
FENTANYL CITRATE - ACTIQ								
020747 004							M-63	Feb 06, 2010
FENTANYL CITRATE - ACTIQ								
020747 005							M-63	Feb 06, 2010
FENTANYL CITRATE - ACTIQ								
020747 006							M-63	Feb 06, 2010

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL CITRATE - FENTORA							
021947 006						**>A>** NDF	Sep 25, 2009
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX							
021520 002	5229382	Apr 23, 2011	DS	DP		NC	Dec 24, 2006
	5229382*PED	Oct 23, 2011				PED	Jun 24, 2007
	5945416	Mar 24, 2017	DS	DP			
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX							
021520 003	5229382	Apr 23, 2011	DS	DP		NC	Dec 24, 2006
	5229382*PED	Oct 23, 2011				PED	Jun 24, 2007
	5945416	Mar 24, 2017	DS	DP			
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX							
021520 004	5229382	Apr 23, 2011	DS	DP		NC	Dec 24, 2006
	5229382*PED	Oct 23, 2011				PED	Jun 24, 2007
	5945416	Mar 24, 2017	DS	DP			
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX							
021520 005	5229382	Apr 23, 2011	DS	DP		NC	Dec 24, 2006
	5229382*PED	Oct 23, 2011				PED	Jun 24, 2007
	5945416	Mar 24, 2017	DS	DP			
FORMOTEROL FUMARATE - FORADIL CERTIHALER							
021592 001	6182655	Dec 05, 2016		DP		NP	Dec 15, 2009
	6645466	Nov 10, 2019		DP			
GALANTAMINE HYDROBROMIDE - RAZADYNE ER							
021615 001	7160559	Dec 20, 2019		DP			
GALANTAMINE HYDROBROMIDE - RAZADYNE ER							
021615 002	7160559	Dec 20, 2019		DP			
GALANTAMINE HYDROBROMIDE - RAZADYNE ER							
021615 003	7160559	Dec 20, 2019		DP			
HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT							
020818 004	5399578	Mar 21, 2012	DS	DP	U-3		
	6294197	Jun 18, 2017		DP	U-3		
HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT							
020818 005	5399578	Mar 21, 2012	DS	DP	U-3		
	6294197	Jun 18, 2017		DP	U-3		
HYDROXOCOBALAMIN - CYANOKIT							
022041 002	5834448	Nov 14, 2016		DP	U-789	ODE	Dec 15, 2013
IBANDRONATE SODIUM - BONIVA							
021455 001	**>A>** 4927814	Jul 09, 2008	DS	DP	U-700		
	>A> 4927814	Jul 09, 2008	DS	DP	U-642		
IBANDRONATE SODIUM - BONIVA							
021455 002	**>A>** 4927814	Jul 09, 2008	DS	DP	U-700		
	>A> 4927814	Jul 09, 2008	DS	DP	U-642		
	>A> 7192938	May 06, 2023			U-798		
IBUPROFEN LYSINE - NEOPROFEN							
021903 001	6342530	Nov 14, 2020	DS	DP	U-794		
	6344479	Mar 20, 2021	DS	DP	U-794		
IMATINIB MESYLATE - GLEEVEC							
021335 001	6958335	Dec 19, 2021			U-791		
	6958335*PED	Jun 19, 2022					
IMATINIB MESYLATE - GLEEVEC							
021335 002	6958335	Dec 19, 2021			U-791		
	6958335*PED	Jun 19, 2022					
IMATINIB MESYLATE - GLEEVEC							
021588 001	6958335	Dec 19, 2021			U-791		
	6958335*PED	Jun 19, 2022					

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IMATINIB MESYLATE - GLEEVEC					
021588 002	6958335	Dec 19, 2021	U-791		
	6958335*PED	Jun 19, 2022			
IRON SUCROSE - VENOFER					
021135 004				**>A>** I-474	Oct 17, 2008
				>A> I-459	Jun 17, 2008
KETOCONAZOLE - XOLEGEL					
021946 001	7179475	Dec 04, 2018	DP U-792		
LAMOTRIGINE - LAMICTAL					
020241 001	4602017	Jul 22, 2008	U-106	I-516	Sep 22, 2009
	4602017*PED	Jan 22, 2009		PED	Mar 22, 2010
LAMOTRIGINE - LAMICTAL					
020241 002	4602017	Jul 22, 2008	U-106	I-516	Sep 22, 2009
	4602017*PED	Jan 22, 2009		PED	Mar 22, 2010
LAMOTRIGINE - LAMICTAL					
020241 003	4602017	Jul 22, 2008	U-106	I-516	Sep 22, 2009
	4602017*PED	Jan 22, 2009		PED	Mar 22, 2010
LAMOTRIGINE - LAMICTAL					
020241 004	4602017	Jul 22, 2008	U-106	I-516	Sep 22, 2009
	4602017*PED	Jan 22, 2009		PED	Mar 22, 2010
LAMOTRIGINE - LAMICTAL					
020241 005	4602017	Jul 22, 2008	U-106	I-516	Sep 22, 2009
	4602017*PED	Jan 22, 2009		PED	Mar 22, 2010
LAMOTRIGINE - LAMICTAL					
020241 006	4602017	Jul 22, 2008	U-106	I-516	Sep 22, 2009
	4602017*PED	Jan 22, 2009		PED	Mar 22, 2010
LAMOTRIGINE - LAMICTAL CD					
020764 001	4602017	Jul 22, 2008	U-106	I-516	Sep 22, 2009
	4602017*PED	Jan 22, 2009		PED	Mar 22, 2010
	5698226	Jan 29, 2012			
	5698226*PED	Jul 29, 2012			
LAMOTRIGINE - LAMICTAL CD					
020764 002	4602017	Jul 22, 2008	U-106	I-516	Sep 22, 2009
	4602017*PED	Jan 22, 2009		PED	Mar 22, 2010
	5698226	Jan 29, 2012			
	5698226*PED	Jul 29, 2012			
LAMOTRIGINE - LAMICTAL CD					
020764 003	4602017	Jul 22, 2008	U-106	I-516	Sep 22, 2009
	4602017*PED	Jan 22, 2009		PED	Mar 22, 2010
	5698226	Jan 29, 2012			
	5698226*PED	Jul 29, 2012			
LAMOTRIGINE - LAMICTAL CD					
020764 004	4602017	Jul 22, 2008	U-106	I-516	Sep 22, 2009
	4602017*PED	Jan 22, 2009		PED	Mar 22, 2010
	5698226	Jan 29, 2012			
	5698226*PED	Jul 29, 2012			
LAPATINIB DITOSYLATE - TYKERB					
022059 001				**>A>** NCE	Mar 13, 2012
LATANOPROST - XALATAN					
020597 001	7163959	Jun 19, 2010	DS		
LENALIDOMIDE - REVLIMID					
021880 001	**>A>** 7189740	Apr 11, 2023	U-769		
LENALIDOMIDE - REVLIMID					
021880 002	**>A>** 7189740	Apr 11, 2023	U-769		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID					
021880 003	**>A>** 7189740	Apr 11, 2023	U-769		
LENALIDOMIDE - REVLIMID					
021880 004	**>A>** 7189740	Apr 11, 2023	U-769		
LEVOFLOXACIN - LEVAQUIN					
020634 001	**>A>** 5053407	Dec 20, 2010		**>A>** D-100	Aug 04, 2008
	>A> 5053407*PED	Jun 20, 2011		**>A>** D-83	Oct 23, 2006
				>A> PED	Feb 04, 2009
				>A> PED	Apr 23, 2007
LEVOFLOXACIN - LEVAQUIN					
020634 002	**>A>** 5053407	Dec 20, 2010		**>A>** D-100	Aug 04, 2008
	>A> 5053407*PED	Jun 20, 2011		**>A>** D-83	Oct 23, 2006
				>A> PED	Feb 04, 2009
				>A> PED	Apr 23, 2007
LEVOFLOXACIN - LEVAQUIN					
020634 003	**>A>** 5053407	Dec 20, 2010		**>A>** D-100	Aug 04, 2008
	>A> 5053407*PED	Jun 20, 2011		**>A>** D-83	Oct 23, 2006
				>A> PED	Apr 23, 2007
				>A> PED	Feb 04, 2009
LEVOFLOXACIN - LEVAQUIN					
020635 001	**>A>** 5043407*PED	Jun 20, 2011		**>A>** D-100	Aug 04, 2008
	>A> 5053407	Dec 20, 2010		**>A>** D-83	Oct 23, 2006
				>A> PED	Feb 04, 2009
				>A> PED	Apr 23, 2007
LEVOFLOXACIN - LEVAQUIN					
020635 004	**>A>** 5043407*PED	Jun 20, 2011		**>A>** D-100	Aug 04, 2008
	>A> 5053407	Dec 20, 2010		**>A>** D-83	Oct 23, 2006
				>A> PED	Apr 23, 2007
				>A> PED	Feb 04, 2009
LEVOFLOXACIN - LEVAQUIN					
021721 001	**>A>** 5053407	Dec 20, 2010	DS U-36	**>A>** D-100	Aug 04, 2008
	>A> 5053407*PED	Jun 20, 2011		**>A>** PED	Feb 04, 2009
	>A> 6806256	Feb 26, 2022	DP		
	>A> 6806256*PED	Aug 26, 2022			
LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
020635 002	**>A>** 5043407*PED	Jun 20, 2011		**>A>** D-100	Aug 04, 2008
	>A> 5053407	Dec 20, 2010		**>A>** D-83	Oct 23, 2006
				>A> PED	Feb 04, 2009
				>A> PED	Apr 23, 2007
LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
020635 003	**>A>** 5043407*PED	Jun 20, 2011		**>A>** D-100	Aug 04, 2008
	>A> 5053407	Dec 20, 2010		**>A>** D-83	Oct 23, 2006
				>A> PED	Feb 04, 2009
				>A> PED	Apr 23, 2007
LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
020635 005	**>A>** 5043407*PED	Jun 20, 2011		**>A>** D-100	Aug 04, 2008
	>A> 5053407	Dec 20, 2010		**>A>** D-83	Oct 23, 2006
				>A> PED	Apr 23, 2007
				>A> PED	Feb 04, 2009
LISDEXAMFETAMINE DIMESYLATE - VYVANSE					
021977 001	**>A>** 7105486	Jun 29, 2023	U-727	NCE	Feb 23, 2012
LISDEXAMFETAMINE DIMESYLATE - VYVANSE					
021977 002	**>A>** 7105486	Jun 29, 2023	U-727	NCE	Feb 23, 2012
LISDEXAMFETAMINE DIMESYLATE - VYVANSE					
021977 003	**>A>** 7105486	Jun 29, 2023	U-727	NCE	Feb 23, 2012
LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS					
020448 001	5489436	Feb 06, 2013	DP		
	6814978	Aug 26, 2021	DP		
LOPINAVIR; RITONAVIR - KALETRA					
021251 001	5914332	Dec 13, 2015	U-351		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOPINAVIR; RITONAVIR - KALETRA								
021906 001		7148359	Jul 19, 2019		DP			
MESALAMINE - LIALDA								
022000 001		6773720	Jun 08, 2020		DP		NP	Jan 16, 2010
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET								
021410 001							M-62	Jan 31, 2010
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET								
021410 002							M-62	Jan 31, 2010
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET								
021410 003							M-62	Jan 31, 2010
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET								
021410 004							M-62	Jan 31, 2010
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET								
021410 005							M-62	Jan 31, 2010
MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION								
021026 001	**>A>**	4911932	Mar 27, 2008		DP	U-718		
MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX								
021598 001		6716830	Sep 29, 2019		DP			
OLANZAPINE - ZYPREXA								
020592 001		5229382	Apr 23, 2011	DS	DP	U-547	I-417	Jan 14, 2007
		5229382	Apr 23, 2011	DS	DP	U-149	PED	Jul 14, 2007
		5229382*PED	Oct 23, 2011					
OLANZAPINE - ZYPREXA								
020592 002		5229382	Apr 23, 2011	DS	DP	U-547	I-417	Jan 14, 2007
		5229382	Apr 23, 2011	DS	DP	U-149	PED	Jul 14, 2007
		5229382*PED	Oct 23, 2011					
OLANZAPINE - ZYPREXA								
020592 003		5229382	Apr 23, 2011	DS	DP	U-547	I-417	Jan 14, 2007
		5229382	Apr 23, 2011	DS	DP	U-149	PED	Jul 14, 2007
		5229382*PED	Oct 23, 2011					
OLANZAPINE - ZYPREXA								
020592 004		5229382	Apr 23, 2011	DS	DP	U-547	I-417	Jan 14, 2007
		5229382	Apr 23, 2011	DS	DP	U-149	PED	Jul 14, 2007
		5229382*PED	Oct 23, 2011					
OLANZAPINE - ZYPREXA								
020592 005		5229382	Apr 23, 2011	DS	DP	U-547	I-417	Jan 14, 2007
		5229382	Apr 23, 2011	DS	DP	U-149	PED	Jul 14, 2007
		5229382*PED	Oct 23, 2011					
OLANZAPINE - ZYPREXA								
020592 006		5229382	Apr 23, 2011	DS	DP	U-547	I-417	Jan 14, 2007
		5229382	Apr 23, 2011	DS	DP	U-149	PED	Jul 14, 2007
		5229382*PED	Oct 23, 2011					
OLANZAPINE - ZYPREXA								
021253 001		5229382	Apr 23, 2011	DS	DP	U-571	NP	Mar 29, 2007
		5229382*PED	Oct 23, 2011				NDF	Mar 29, 2007
							PED	Sep 29, 2007
							PED	Sep 29, 2007
OLANZAPINE - ZYPREXA ZYDIS								
021086 001		5229382	Apr 23, 2011			U-324	I-400	Jul 10, 2006
		5229382*PED	Oct 23, 2011				I-417	Jan 14, 2007
							PED	Jan 10, 2007
							PED	Jul 14, 2007
OLANZAPINE - ZYPREXA ZYDIS								
021086 002		5229382	Apr 23, 2011			U-324	I-400	Jul 10, 2006
		5229382*PED	Oct 23, 2011				I-417	Jan 14, 2007
							PED	Jan 10, 2007
							PED	Jul 14, 2007

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLANZAPINE - ZYPREXA ZYDIS								
021086 003		5229382	Apr 23, 2011			U-324	I-400	Jul 10, 2006
		5229382*PED	Oct 23, 2011				I-417	Jan 14, 2007
							PED	Jan 10, 2007
							PED	Jul 14, 2007
OLANZAPINE - ZYPREXA ZYDIS								
021086 004		5229382	Apr 23, 2011			U-324	I-400	Jul 10, 2006
		5229382*PED	Oct 23, 2011				I-417	Jan 14, 2007
							PED	Jan 10, 2007
							PED	Jul 14, 2007
ONDANSETRON - ONDANSETRON								
076506 001							PC	Jun 24, 2007
ONDANSETRON - ONDANSETRON								
076506 002							PC	Jun 24, 2007
ONDANSETRON HYDROCHLORIDE - ONDANSETRON HYDROCHLORIDE								
076183 001							PC	Jun 24, 2007
ONDANSETRON HYDROCHLORIDE - ONDANSETRON HYDROCHLORIDE								
076183 002							PC	Jun 24, 2007
ONDANSETRON HYDROCHLORIDE - ONDANSETRON HYDROCHLORIDE								
076183 003							PC	Jun 24, 2007
ORLISTAT - ALLI								
021887 001	**>A>**	4598089	Jun 18, 2009	DS	DP		**>A>** NP	Feb 07, 2010
	>A>	6004996	Jan 06, 2018		DP			
OXALIPLATIN - ELOXATIN								
021492 001							M-61	Jan 10, 2010
							PED	Jul 10, 2010
OXALIPLATIN - ELOXATIN								
021492 002							M-61	Jan 10, 2010
							PED	Jul 10, 2010
OXALIPLATIN - ELOXATIN								
021759 001		5420319	Aug 09, 2016	DS				
		5420319*PED	Feb 09, 2017					
OXALIPLATIN - ELOXATIN								
021759 002		5420319	Aug 09, 2016	DS				
		5420319*PED	Feb 09, 2017					
OXALIPLATIN - ELOXATIN								
021759 003		5290961	Jan 12, 2013	DS				
		5290961*PED	Jul 12, 2013					
		5338874	Apr 07, 2013	DS				
		5338874*PED	Oct 07, 2013					
		5420319	Aug 09, 2016	DS				
		5420319*PED	Feb 09, 2017					
		5716988	Aug 07, 2015		DP			
		5716988*PED	Feb 07, 2016					
OXCARBAZEPINE - TRILEPTAL								
021014 001		7037525	Feb 12, 2018			U-724		
		7037525*PED	Aug 12, 2018					
OXCARBAZEPINE - TRILEPTAL								
021014 002		7037525	Feb 12, 2018			U-724		
		7037525*PED	Aug 12, 2018					
OXCARBAZEPINE - TRILEPTAL								
021014 003		7037525	Feb 12, 2018			U-724		
		7037525*PED	Aug 12, 2018					
OXYBUTYNIN - OXYTROL								
021351 002		7179483	Apr 26, 2020	DS	DP	U-318		
PALIPERIDONE - INVEGA								
021999 001		5158952	Oct 27, 2009		DP	U-90		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALIPERIDONE - INVEGA					
021999 002	5158952	Oct 27, 2009	DP U-90		
PALIPERIDONE - INVEGA					
021999 003	5158952	Oct 27, 2009	DP U-90		
PALIPERIDONE - INVEGA					
021999 004	5158952	Oct 27, 2009	DP U-90		
PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE					
077395 001				PC	Jun 10, 2007
PAROXETINE HYDROCHLORIDE - PAXIL CR					
020936 001	5789449	Jan 06, 2009	U-788		
	5789449*PED	Jul 06, 2009			
PAROXETINE HYDROCHLORIDE - PAXIL CR					
020936 002	5789449	Jan 06, 2009	U-788		
	5789449*PED	Jul 06, 2009			
PAROXETINE HYDROCHLORIDE - PAXIL CR					
020936 003	5789449	Jan 06, 2009	U-788		
	5789449*PED	Jul 06, 2009			
RANITIDINE HYDROCHLORIDE - RANITIDINE HYDROCHLORIDE					
076124 001				>A> PC	Sep 15, 2007
RISPERIDONE - RISPERDAL					
020272 001	4804663	Dec 29, 2007	U-90	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008		I-413	Dec 04, 2006
				I-412	Dec 04, 2006
				PED	Jun 04, 2007
				PED	Jun 04, 2007
				PED	Apr 06, 2010
RISPERIDONE - RISPERDAL					
020272 002	4804663	Dec 29, 2007	U-90	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008		I-413	Dec 04, 2006
				I-412	Dec 04, 2006
				PED	Jun 04, 2007
				PED	Jun 04, 2007
				PED	Apr 06, 2010
RISPERIDONE - RISPERDAL					
020272 003	4804663	Dec 29, 2007	U-90	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008		I-413	Dec 04, 2006
				I-412	Dec 04, 2006
				PED	Jun 04, 2007
				PED	Jun 04, 2007
				PED	Apr 06, 2010
RISPERIDONE - RISPERDAL					
020272 004	4804663	Dec 29, 2007	U-90	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008		I-413	Dec 04, 2006
				I-412	Dec 04, 2006
				PED	Jun 04, 2007
				PED	Jun 04, 2007
				PED	Apr 06, 2010
RISPERIDONE - RISPERDAL					
020272 005	4804663	Dec 29, 2007	U-90	I-413	Dec 04, 2006
	4804663*PED	Jun 29, 2008		I-412	Dec 04, 2006
				PED	Jun 04, 2007
				PED	Jun 04, 2007
RISPERIDONE - RISPERDAL					
020272 007	4804663	Dec 29, 2007	U-90	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008		I-413	Dec 04, 2006
				I-412	Dec 04, 2006
				PED	Jun 04, 2007
				PED	Jun 04, 2007
				PED	Apr 06, 2010

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - RISPERDAL					
020272 008	4804663	Dec 29, 2007	U-90	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008		I-413	Dec 04, 2006
				I-412	Dec 04, 2006
				PED	Jun 04, 2007
				PED	Jun 04, 2007
				PED	Apr 06, 2010
RISPERIDONE - RISPERDAL					
020588 001	4804663	Dec 29, 2007	U-90	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008		I-413	Dec 04, 2006
	5453425	Jul 11, 2014		I-412	Dec 04, 2006
	5453425*PED	Jan 11, 2015		PED	Apr 06, 2010
	5616587	Jul 11, 2014		PED	Jun 04, 2007
	5616587*PED	Jan 11, 2015		PED	Jun 04, 2007
	RE39181	Jul 11, 2014	DP		
	RE39181*PED	Jan 11, 2015			
RISPERIDONE - RISPERDAL					
021444 001	4804663	Dec 29, 2007	DS DP U-516	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008		I-413	Dec 04, 2006
	5648093	Jul 15, 2014	DP	I-412	Dec 04, 2006
	5648093*PED	Jan 15, 2015		PED	Jun 04, 2007
	6224905	Jun 10, 2017	DP	PED	Jun 04, 2007
	6244905*PED	Dec 10, 2017		PED	Apr 06, 2010
RISPERIDONE - RISPERDAL					
021444 002	4804663	Dec 29, 2007	DS DP U-516	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008		I-413	Dec 04, 2006
	5648093	Jul 15, 2014	DP	I-412	Dec 04, 2006
	5648093*PED	Jan 15, 2015		PED	Jun 04, 2007
	6224905	Jun 10, 2017	DP	PED	Jun 04, 2007
	6244905*PED	Dec 10, 2017		PED	Apr 06, 2010
RISPERIDONE - RISPERDAL					
021444 003	4804663	Dec 29, 2007	DS DP U-516	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008		I-413	Dec 04, 2006
	5648093	Jul 15, 2014	DP	I-412	Dec 04, 2006
	5648093*PED	Jan 15, 2015		PED	Apr 06, 2010
	6224905	Jun 10, 2017	DP	PED	Jun 04, 2007
	6244905*PED	Dec 10, 2017		PED	Jun 04, 2007
RISPERIDONE - RISPERDAL					
021444 004	4804663	Dec 29, 2007	DS DP U-516	I-509	Oct 06, 2009
	4804663	Dec 29, 2007	DS DP U-543	I-413	Dec 04, 2006
	4804663*PED	Jun 29, 2008		I-412	Dec 04, 2006
	5648093	Jul 15, 2014	DP	PED	Jun 04, 2007
	5648093*PED	Jan 15, 2015		PED	Jun 04, 2007
	6224905	Jun 10, 2017	DP	PED	Apr 06, 2010
	6244905*PED	Dec 10, 2017			
RISPERIDONE - RISPERDAL					
021444 005	4804663	Dec 29, 2007	DS DP U-516	I-509	Oct 06, 2009
	4804663	Dec 29, 2007	DS DP U-543	I-413	Dec 04, 2006
	4804663*PED	Jun 29, 2008		I-412	Dec 04, 2006
	5648093	Jul 15, 2014	DP	PED	Jun 04, 2007
	5648093*PED	Jan 15, 2015		PED	Jun 04, 2007
	6224905	Jun 10, 2017	DP	PED	Apr 06, 2010
	6244905*PED	Dec 10, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - RISPERDAL CONSTA					
021346 001	4804663	Dec 29, 2007		NDF	Oct 29, 2006
	4804663*PED	Jun 29, 2008		PED	Apr 29, 2007
	5688801	Nov 18, 2014			
	5688801*PED	May 18, 2015			
	5770231	Nov 19, 2013			
	5770231*PED	May 19, 2014			
	5792477	May 02, 2017			
	5792477*PED	Nov 02, 2017			
	5916598	May 02, 2017			
	5916598*PED	Nov 02, 2017			
	5965168	Nov 19, 2013			
	5965168*PED	May 19, 2014			
	6110503	May 02, 2017			
	6110503*PED	Nov 02, 2017			
	6110921	Nov 19, 2013			
	6110921*PED	May 19, 2014			
	6194006	Dec 30, 2018			
	6194006*PED	Jun 30, 2019			
	6264987	May 19, 2020			
	6264987*PED	Nov 19, 2020			
	6368632	Nov 19, 2013	U-543		
	6368632*PED	May 19, 2014			
	6379703	Dec 30, 2018	DP		
	6379703*PED	Jun 30, 2019			
	6379704	May 19, 2020	DP		
	6379704*PED	Nov 19, 2020			
	6403114	May 02, 2017			
	6403114*PED	Nov 02, 2017			
	6534092	May 19, 2020	DP		
	6534092*PED	Nov 19, 2020			
	6596316	Dec 30, 2008	DP		
	6596316*PED	Jun 30, 2009			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - RISPERDAL CONSTA					
021346 002	4804663	Dec 29, 2007		NDF	Oct 29, 2006
	4804663*PED	Jun 29, 2008		PED	Apr 29, 2007
	5688801	Nov 18, 2014			
	5688801*PED	May 18, 2015			
	5770231	Nov 19, 2013			
	5770231*PED	May 19, 2014			
	5792477	May 02, 2017			
	5792477*PED	Nov 02, 2017			
	5916598	May 02, 2017			
	5916598*PED	Nov 02, 2017			
	5965168	Nov 19, 2013			
	5965168*PED	May 19, 2014			
	6110503	May 02, 2017			
	6110503*PED	Nov 02, 2017			
	6110921	Nov 19, 2013			
	6110921*PED	May 19, 2014			
	6194006	Dec 30, 2018			
	6194006*PED	Jun 30, 2019			
	6264987	May 19, 2020			
	6264987*PED	Nov 19, 2020			
	6368632	Nov 19, 2013	U-543		
	6368632*PED	May 19, 2014			
	6379703	Dec 30, 2018	DP		
	6379703*PED	Jun 30, 2019			
	6379704	May 19, 2020	DP		
	6379704*PED	Nov 19, 2020			
	6403114	May 02, 2017			
	6403114*PED	Nov 02, 2017			
	6534092	May 19, 2020	DP		
	6534092*PED	Nov 19, 2020			
	6596316	Dec 30, 2008	DP		
	6596316*PED	Jun 30, 2009			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - RISPERDAL CONSTA								
021346 003		4804663	Dec 29, 2007				NDF	Oct 29, 2006
		4804663*PED	Jun 29, 2008				PED	Apr 29, 2007
		5688801	Nov 18, 2014					
		5688801*PED	May 18, 2015					
		5770231	Nov 19, 2013					
		5770231*PED	May 19, 2014					
		5792477	May 02, 2017					
		5792477*PED	Nov 02, 2017					
		5916598	May 02, 2017					
		5916598*PED	Nov 02, 2017					
		5965168	Nov 19, 2013					
		5965168*PED	May 19, 2014					
		6110503	May 02, 2017					
		6110503*PED	Nov 02, 2017					
		6110921	Nov 19, 2013					
		6110921*PED	May 19, 2014					
		6194006	Dec 30, 2018					
		6194006*PED	Jun 30, 2019					
		6264987	May 19, 2020					
		6264987*PED	Nov 19, 2020					
		6368632	Nov 19, 2013			U-543		
		6368632*PED	May 19, 2014					
		6379703	Dec 30, 2018		DP			
		6379703*PED	Jun 30, 2019					
		6379704	May 19, 2020		DP			
		6379704*PED	Nov 19, 2020					
		6403114	May 02, 2017					
		6403114*PED	Nov 02, 2017					
		6534092	May 19, 2020		DP			
		6534092*PED	Nov 19, 2020					
		6596316	Dec 30, 2008		DP			
		6596316*PED	Jun 30, 2009					
SELEGILINE - EMSAM								
021336 001		7150881	Jun 12, 2018	DS	DP			
SELEGILINE - EMSAM								
021336 002		7150881	Jun 12, 2018	DS	DP			
SELEGILINE - EMSAM								
021336 003		7150881	Jun 12, 2018	DS	DP			
SOMATROPIN RECOMBINANT - SAIZEN								
019764 005							I-440	Aug 26, 2007
TADALAFIL - CIALIS								
021368 001	**>A>**	7182958	Apr 26, 2020		DP	U-155		
TADALAFIL - CIALIS								
021368 002	**>A>**	7182958	Apr 26, 2020		DP	U-155		
TADALAFIL - CIALIS								
021368 003	**>A>**	7182958	Apr 26, 2020		DP	U-155		
TERIPARATIDE RECOMBINANT HUMAN - FORTEO								
021318 001		7163684	Aug 19, 2019			U-790		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID					
020785 004	5629327	May 13, 2014	U-731	ODE	May 23, 2013
	6045501	Aug 28, 2018	U-731		
	6235756	Mar 01, 2013	U-731		
	6315720	Oct 23, 2020	U-731		
	6561976	Aug 28, 2018	U-731		
	6561977	Oct 23, 2020	U-731		
	6755784	Oct 23, 2020	U-731		
	6869399	Oct 23, 2020	U-731		
	6908432	Aug 28, 2018	U-731		
	7141018	Oct 23, 2020	U-731		
TIMOLOL MALEATE - TIMOLOL MALEATE					
020963 001	6174524	Mar 26, 2019			
	6174524*PED	Sep 26, 2019			
TIMOLOL MALEATE - TIMOLOL MALEATE					
020963 002	6174524	Mar 26, 2019			
	6174524*PED	Sep 26, 2019			
ZIPRASIDONE HYDROCHLORIDE - GEODON					
021483 001	7175855	May 18, 2020	DP		
ZOLPIDEM TARTRATE - AMBIEN					
019908 001				**>A>** M-54	Mar 29, 2010
				>A> PED	Sep 29, 2010
ZOLPIDEM TARTRATE - AMBIEN					
019908 002				**>A>** M-54	Mar 29, 2010
				>A> PED	Sep 29, 2010

Footnotes:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
   DS = Drug Substance claim
   DP = Drug Product claim
   U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at http://www.fda.gov/cder/orange/patex.htm
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.
5. *** U.S. Patent Nos. RE 36481 and RE 36520 were relisted for Zocor (NDA 19-766) pursuant to the decision and related order in Ranbaxy Labs. v.Leavitt, No. 05-1838 (D.D.C. April 30, 2006). The '481 and '520 patents remained listed in Approved Drug Products with Therapeutic Equivalence Evaluations until any applicable periods of exclusivity pursuant to section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act were triggered and run. For additional information on this matter, please refer to Docket Nos. 2005P-0008 and 2005P-0046. Patents were subsequently delisted in the December 2006 Orange Book update as the exclusivity periods have triggered and run to expiration.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 27th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm